Herbert Y. Meltzer

Herbert Y. Meltzer's AcademicInfluence.com Rankings

Herbert Y. Meltzer

Medical

#241

World Rank

#358

Historical Rank

#112

USA Rank

Pharmacology

#12

World Rank

#18

Historical Rank

USA Rank

medical Degrees

Herbert Y. Meltzer

Philosophy

#1370

World Rank

#2520

Historical Rank

#551

USA Rank

Logic

#187

World Rank

#422

Historical Rank

#86

USA Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Herbert Y. Meltzer Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Herbert Y. Meltzer is an American scientist and professor of psychiatry and behavioral sciences, pharmacology and physiology and director of the Translational Neuropharmacology Program at Northwestern University, best known for his research on the treatment of schizophrenia. He is the author of over 1,000 publications.

(See a Problem?)

Herbert Y. Meltzer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Psychopharmacology : the third generation of progress (1987) (1922)
Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression∗ ∗ See accompanying Editorial, in this issue. (1999) (1433)
Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. (1989) (1326)
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). (2003) (1196)
Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III (2005) (1160)
The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. (1999) (1036)
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. (2007) (1009)
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. (2006) (916)
The dopamine hypothesis of schizophrenia: a review. (1976) (840)
Serotonin receptors : their key role in drugs to treat schizophrenia (2003) (764)
The Role of Serotonin in Antipsychotic Drug Action (1999) (697)
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. (1994) (669)
Cellular changes in the postmortem hippocampus in major depression (2004) (660)
H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs (2003) (633)
Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. (1995) (607)
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. (2017) (567)
A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. (2005) (556)
5‐HT2A and D2 receptor blockade increases cortical DA release via 5‐HT1A receptor activation: a possible mechanism of atypical antipsychotic‐induced cortical dopamine release (2001) (518)
A novel augmentation strategy for treating resistant major depression. (2001) (497)
Practice guideline for the assessment and treatment of patients with suicidal behaviors. (2003) (488)
Lowered ω3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients (1999) (477)
Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial (2006) (476)
A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia (2009) (462)
Eye-tracking dysfunctions in schizophrenic patients and their relatives. (1974) (457)
Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. (1995) (450)
Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression (1993) (424)
Reduced Levels of Norepinephrine Transporters in the Locus Coeruleus in Major Depression (1997) (413)
Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine (1993) (406)
Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: The MIND randomized, placebo-controlled trial* (2010) (405)
Treatment-resistant schizophrenia--the role of clozapine. (1997) (404)
Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. (1995) (398)
The mechanism of action of novel antipsychotic drugs. (1991) (397)
Identification of vascular structures as a major source of signal contrast in high resolution 2D and 3D functional activation imaging of the motor cortex at l.5T preliminary results (1993) (379)
Cloning, Characterization, and Chromosomal Localization of a Human 5‐HT6 Serotonin Receptor (1996) (366)
Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. (1999) (366)
Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? (1993) (358)
Outcome in manic disorders. A naturalistic follow-up study. (1990) (355)
Increased Depressive Ratings in Patients With Hepatitis C Receiving Interferon-α–Based Immunotherapy Are Related to Interferon-α–Induced Changes in the Serotonergic System (2002) (351)
The role of cognition in vocational functioning in schizophrenia (2000) (351)
Update on typical and atypical antipsychotic drugs. (2013) (347)
Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs (1997) (335)
Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. (1990) (334)
The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. (1989) (331)
Serotonergic measures in the brains of suicide victims: 5-HT2 binding sites in the frontal cortex of suicide victims and control subjects. (1989) (320)
The role of serotonin receptors in the action of atypical antipsychotic drugs. (2011) (316)
Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. (2004) (315)
Fatty acid composition in major depression: decreased ω3 fractions in cholesteryl esters and increased C20:4ω6C20:5ω3 ratio in cholesteryl esters and phospholipids (1996) (315)
Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia (2004) (298)
Suicide risk in schizophrenia: learning from the past to change the future (2007) (294)
Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat Evidence for opposing roles of 5-HT2 and 5-HT1A receptors (1986) (286)
The effect of neuroleptics on serum prolactin in schizophrenic patients. (1976) (283)
Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder (2000) (283)
Effects of antipsychotic drugs on serotonin receptors. (1991) (281)
Treatment of the neuroleptic-nonresponsive schizophrenic patient. (1992) (280)
An overview of the mechanism of action of clozapine. (1994) (280)
Lower serum high‐density lipoprotein cholesterol (HDL‐C) in major depression and in depressed men with serious suicidal attempts: relationship with immune‐inflammatory markers (1997) (279)
Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: Further evidence for an immune response (1994) (273)
Role of Serotonin in Depression a (1990) (265)
Meta-analyses of studies of ventricular enlargement and cortical sulcal prominence in mood disorders. Comparisons with controls or patients with schizophrenia. (1995) (265)
Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo (2009) (259)
RNA Editing of the Human Serotonin 5-HT2C Receptor: Alterations in Suicide and Implications for Serotonergic Pharmacotherapy (2001) (252)
Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness (1997) (250)
Atypical, but Not Typical, Antipsychotic Drugs Increase Cortical Acetylcholine Release without an Effect in the Nucleus Accumbens or Striatum (2002) (244)
Pharmacogenetics of Tardive Dyskinesia: Combined Analysis of 780 Patients Supports Association with Dopamine D3 Receptor Gene Ser9Gly Polymorphism (2002) (239)
In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. (2008) (238)
Clozapine for treatment-refractory mania. (1996) (238)
Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis (2010) (238)
Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats. (1979) (237)
Serotonin Subtype 2 Receptor Genes and Clinical Response to Clozapine in Schizophrenia Patients (1998) (233)
Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. (2002) (231)
Hopelessness, neurocognitive function, and insight in schizophrenia: relationship to suicidal behavior (2003) (229)
Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. (1997) (226)
Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. (2001) (225)
Serotonin uptake in blood platelets of psychiatric patients. (1981) (225)
Assessment of negative and positive symptoms in schizophrenia. (1983) (221)
Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection (2008) (220)
Effects of clozapine on cognitive function in schizophrenia. (1994) (218)
Common variants conferring risk of schizophrenia: A pathway analysis of GWAS data (2010) (216)
Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. (1992) (215)
The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine (2004) (214)
Effects of phencyclidine on [3H]catecholamine and [3H]serotonin uptake in synaptosomal preparations from rat brain. (1977) (212)
Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. (1993) (210)
Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. (2004) (206)
Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. (2011) (205)
Stimulation of corticosterone and beta-endorphin secretion in the rat by selective 5-HT receptor subtype activation. (1987) (204)
Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. (1993) (203)
Seasonality in violent suicide but not in nonviolent suicide or homicide. (1993) (203)
Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. (1988) (198)
Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia (2002) (198)
Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. I. Enhanced response in depression and mania. (1984) (197)
Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. (2001) (197)
Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. (1996) (195)
Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism (2002) (193)
A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. (2005) (185)
Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. (2012) (181)
Role of serotonin in the action of atypical antipsychotic drugs. (1990) (180)
A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study (2002) (177)
Increased serotonin2 (5-HT2) receptor binding as measured by 3H-lysergic acid diethylamide (3H-LSD) in the blood platelets of depressed patients. (1989) (177)
Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. (1993) (176)
Clozapine: balancing safety with superior antipsychotic efficacy. (2012) (175)
In vivo immunomodulatory effects of clozapine in schizophrenia (1997) (175)
Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. (2004) (169)
A kinetic and pharmacologic analysis of 5-hydroxytryptamine transport by human platelets and platelet storage granules: comparison with central serotonergic neurons. (1978) (167)
What's atypical about atypical antipsychotic drugs? (2004) (167)
Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs (1995) (167)
Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia (1996) (166)
2D and 3D high resolution gradient echo functional imaging of the brain: Venous contributions to signal in motor cortex studies (1994) (165)
Fluoxetine in the treatment of borderline and schizotypal personality disorders. (1991) (163)
Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. (1997) (162)
Association of the MscI Polymorphism of the Dopamine D3 Receptor Gene with Tardive Dyskinesia in Schizophrenia (1999) (162)
Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression (1995) (161)
Effect of clozapine on human serum prolactin levels. (1979) (161)
Does stimulation of 5-HT1A receptors improve cognition in schizophrenia? (2008) (160)
Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. (2008) (160)
Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study (2003) (158)
Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. (1994) (157)
Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (1997) (155)
Cortical localization of human sustained attention: detection with functional MR using a visual vigilance paradigm. (1996) (154)
The Effect of Neuroleptics and Other Psychotropic Drugs on Negative Symptoms in Schizophrenia (1986) (152)
Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. (2001) (152)
Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. (1999) (151)
Serotonin Receptors in Suicide Victims with Major Depression (1997) (150)
Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression (1993) (150)
WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Preclinical Antipsychotic-Like Activity (2007) (149)
Efficacy and Safety of Donepezil in Patients with Schizophrenia or Schizoaffective Disorder: Significant Placebo/Practice Effects in a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial (2008) (147)
Lateral ventricular size, psychopathology, and medication response in the psychoses. (1984) (145)
Effect of diagnostic criteria on the ratio of male to female schizophrenic patients. (1984) (144)
The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia (2001) (143)
Glucocorticoid receptors in depression: relationship to the dexamethasone suppression test. (1985) (140)
A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: Dose effects and comparison to practice effects (2007) (139)
Elevated levels of tyrosine hydroxylase in the locus coeruleus in major depression (1999) (138)
Marked Elevations of Serum Creatine Kinase Activity Associated with Antipsychotic Drug Treatment (1996) (138)
The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia. (2014) (136)
Clozapine-induced weight gain predicts improvement in psychopathology (2003) (136)
The relationship between smooth pursuit performance, motion perception and sustained visual attention in patients with schizophrenia and normal controls (1997) (136)
Clinical services research. (1992) (135)
Human platelet α2-adrenergic receptors: Labeling with 3H-yohimbine, a selective antagonist ligand (1981) (135)
Cognition, schizophrenia, and the atypical antipsychotic drugs. (1999) (134)
Family expressed emotion and relapse in schizophrenia in 24 urban American patients. (1985) (133)
Dopamine D2 Receptor Levels in Striatum, Thalamus, Substantia Nigra, Limbic Regions, and Cortex in Schizophrenic Subjects (2009) (132)
A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia (1999) (132)
Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. (2015) (132)
Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: A randomized, double-blind, placebo-controlled study (2007) (132)
ACNP Task Force Report on SSRIs and Suicidal Behavior in Youth (2006) (132)
Biological studies in schizophrenia. (1987) (131)
N-Desmethylclozapine, a Major Metabolite of Clozapine, Increases Cortical Acetylcholine and Dopamine Release In Vivo Via Stimulation of M1 Muscarinic Receptors (2005) (130)
Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. II. Relation to suicide, psychosis, and depressive symptoms. (1984) (129)
The Importance of Serotonin-Dopamine Interactions in the Action of Clozapine (1992) (129)
A prospective study of clozapine in treatment-resistant schizophrenic patients (2004) (129)
5-HT2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner (2002) (128)
Serum dopamine-beta-hydroxylase activity in the affective psychoses and schizophrenia. Decreased activity in unipolar psychotically depressed patients. (1976) (128)
A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. (2008) (128)
Factors affecting serum creatine phosphokinase levels in the general population: the role of race, activity and age. (1971) (127)
Lower serum prolyl endopeptidase enzyme activity in major depression: Further evidence that peptidases play a role in the pathophysiology of depression (1994) (125)
Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. (2007) (125)
Alterations in phosphoinositide signaling and G-protein levels in depressed suicide brain (1996) (125)
Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement. (2010) (124)
The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine’s actions? (2005) (123)
Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs (1999) (123)
Occupancy of Striatal and Extrastriatal Dopamine D2 Receptors by Clozapine and Quetiapine (2006) (122)
Effect of Intramuscular Injections on Serum Creatine Phosphokinase Activity (1970) (122)
Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs (1996) (121)
Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. (2005) (120)
Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial. (2004) (118)
Quantitative assessment of smooth pursuit gain and catch-up saccades in schizophrenia and affective disorders (1991) (118)
The Role of 5-Hydroxytryptamine 7 Receptors in the Phencyclidine-Induced Novel Object Recognition Deficit in Rats (2011) (117)
Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression (1995) (117)
Plasma ACTH and cortisol levels in depressed patients: relation to dexamethasone suppression test. (1981) (116)
Effect of dexamethasone on plasma prolactin and cortisol levels in psychiatric patients. (1982) (116)
Effect of antidepressants on striatal and accumbens extracellular dopamine levels. (1995) (115)
The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment (2011) (115)
5-hydroxytryptamine1A receptor-mediated effects of buspirone, gepirone and ipsapirone (1988) (115)
Dr. Meltzer and Mr. Cola Reply (1995) (113)
Thought pathology in manic and schizophrenic patients. Its occurrence at hospital admission and seven weeks later. (1982) (112)
Treatment with interferon-alpha (IFNα) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFNα-induced depressive and anxiety symptoms and immune activation (2001) (112)
Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. (2003) (112)
Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. (2010) (109)
The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia (2013) (108)
Outcome in schizophrenia: beyond symptom reduction. (1999) (108)
Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms. (1984) (108)
Neuropsychologic deficits in schizophrenia : Relation to social function and effect of antipsychotic drug treatment (1996) (108)
Glucocorticoid resistance in depression: the dexamethasone suppression test and lymphocyte sensitivity to dexamethasone. (1984) (107)
−759C/genetic variation of 5HT2C receptor and clozapine-induced weight gain (2002) (107)
Commentary on "Clinical studies on the mechanism of action of clozapine; the dopamine–serotonin hypothesis of schizophrenia." Psychopharmacology (1989) 99:S18–S27 (2002) (105)
A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. (2015) (105)
Suicidality in schizophrenia: A review of the evidence for risk factors and treatment options (2002) (105)
Gene Expression Profiling in Postmortem Prefrontal Cortex of Major Depressive Disorder (2007) (105)
COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia (2007) (105)
Defining treatment refractoriness in schizophrenia. (1990) (105)
NK3 receptor antagonists: the next generation of antipsychotics? (2005) (104)
Treatment of Suicidality in Schizophrenia (2001) (102)
Serum prolactin levels in unmedicated schizophrenic patients. (1974) (102)
The effect of serotonin1A receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens (2000) (102)
Association study of 12 polymorphisms spanning the dopamine D2 receptor gene and clozapine treatment response in two treatment refractory/intolerant populations (2005) (101)
Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. (2012) (101)
Novel antipsychotic drugs (1992) (100)
Clozapine: is another view valid? (1995) (100)
Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder: A Randomized, Double-Blind, Fixed-Dose Study (2008) (100)
A Common Polymorphism in the Cannabinoid Receptor 1 (CNR1) Gene is Associated with Antipsychotic-Induced Weight Gain in Schizophrenia (2010) (98)
Clozapine alone versus clozapine and risperidone for refractory schizophrenia. (2006) (97)
Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism (2004) (97)
Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. (1998) (97)
Exome sequencing followed by large-scale genotyping suggests a limited role for moderately rare risk factors of strong effect in schizophrenia. (2012) (97)
Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia (2004) (96)
Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia (1991) (95)
The effect of buspirone on prolactin and growth hormone secretion in man. (1983) (95)
Reduced glial and neuronal packing density in the orbitofrontal cortex in alcohol dependence and its relationship with suicide and duration of alcohol dependence. (2006) (94)
Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia. (2013) (93)
Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex. (1989) (93)
Randomized controlled trial of deutetrabenazine for tardive dyskinesia (2017) (92)
Suicide in schizophrenia: risk factors and clozapine treatment. (1998) (92)
Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. (1999) (92)
Serotonergic mechanisms as targets for existing and novel antipsychotics. (2012) (91)
Gender-specific decrease in NUDR and 5-HT1A receptor proteins in the prefrontal cortex of subjects with major depressive disorder. (2009) (91)
Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. (2013) (90)
Attention and higher cortical functions in schizophrenia. (1991) (90)
Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine (2000) (89)
Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. III. Effect of antidepressants and lithium carbonate. (1984) (89)
Attenuation of Phencyclidine-Induced Object Recognition Deficits by the Combination of Atypical Antipsychotic Drugs and Pimavanserin (ACP 103), a 5-Hydroxytryptamine2A Receptor Inverse Agonist (2010) (88)
Seasonality in severity of depression: relationships to suicide and homicide occurrence (1993) (88)
Stimulation of serum cortisol and prolactin secretion in humans by MK-212, a centrally active serotonin agonist (1988) (88)
Biology of schizophrenia subtypes: a review and proposal for method of study. (1979) (88)
Serotonergic measures in suicide brain: 5-HT1A binding sites in frontal cortex of suicide victims (1991) (88)
Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia (2001) (87)
Lack of association between the T→C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia (2001) (87)
Relevance of dopamine autoreceptors for psychiatry: preclinical and clinical studies. (1980) (87)
An unstable trinucleotide-repeat region on chromosome 13 implicated in spinocerebellar ataxia: a common expansion locus. (2000) (85)
N‐desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis (1994) (85)
Phencyclidine-induced rotational behavior in rats with nigrostriatal lesions and its modulation by dopaminergic and cholinergic agents (1976) (85)
Effect of quipazine on rat plasma prolactin levels. (1976) (83)
Effects of ipsapirone on plasma cortisol and body temperature in major depression (1995) (83)
The Role of Serotonin in Schizophrenia and the Place of Serotonin‐Dopamine Antagonist Antipsychotics (1995) (83)
SR46349-B, a 5-HT2A/2C Receptor Antagonist, Potentiates Haloperidol-induced Dopamine Release in Rat Medial Prefrontal Cortex and Nucleus Accumbens (2002) (83)
Effects of buspirone on plasma prolactin and cortisol levels in major depressed and normal subjects (1994) (83)
Differential Effect of Subchronic Treatment with Various Neuroleptic Agents on Serotonin2 Receptors in Rat Cerebral Cortex (1986) (82)
Occupancy of Striatal and Extrastriatal Dopamine D2/D3 Receptors by Olanzapine and Haloperidol (2005) (82)
R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. (1999) (81)
The effect of phencyclidine on dopamine synthesis and metabolic in rat striatum. (1980) (81)
Brain region effects of clozapine on amino acid and monoamine transmission. (1994) (81)
Suicide and schizophrenia: clozapine and the InterSePT study. International Clozaril/Leponex Suicide Prevention Trial. (1999) (80)
Seasonal variation of serotonin uptake in normal controls and depressed patients. (1984) (80)
The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats (2012) (80)
DOI, a 5-HT2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum (1995) (80)
Plasma-soluble interleukin-2 and transferrin receptor in schizoprenia and major depression (1995) (80)
The Longitudinal Course of Schizoaffective Disorders: A Prospective Follow-up Study (1984) (80)
Serotonin 5-HT2C agonists selectively inhibit morphine-induced dopamine efflux in the nucleus accumbens (1998) (79)
Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. (2007) (78)
Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder. (1990) (77)
Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day (2012) (77)
alpha 2-Adrenergic receptors in platelet membranes of depressed patients: no change in number of 3H-yohimbine affinity. (1981) (77)
R(+)-8-OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbens. (1995) (77)
Platelet Markers of Suicidality a (1986) (76)
Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and the nucleus accumbens. (1991) (76)
Clozapine prophylaxis in rapid cycling bipolar disorder. (1991) (76)
Serotonin uptake and imipramine binding in blood platelets and brain of Fawn-hooded and Sprague Dawley rats. (1983) (76)
Fluoxetine, but not Tricyclic Antidepressants, Potentiates the 5-Hydroxytryptophan-Mediated Increase in Plasma Cortisol and Prolactin Secretion in Subjects with Major Depression or with Obsessive Compulsive Disorder (1997) (76)
Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. (2002) (76)
Dexamethasone bioavailability: Implications for DST research (1987) (76)
Valproate and carbamazepine increase prefrontal dopamine release by 5-HT1A receptor activation. (1999) (75)
Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression (1996) (75)
An evaluation of basal hypothalamic-pituitary-thyroid axis function in depression: Results of a large-scaled and controlled study (1993) (75)
Psychomotor retardation, anorexia, weight loss, sleep disturbances, and loss of energy: Psychopathological correlates of hyperhaptoglobinemia during major depression (1993) (75)
Treatment of schizophrenia and spectrum disorders: pharmacotherapy, psychosocial treatments, and neurotransmitter interactions (1999) (75)
Genetic variant near cytosolic phospholipase A2 associated with schizophrenia (1996) (74)
Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a brief report. (2010) (73)
5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. (2002) (73)
Pre-clinical Pharmacology of Atypical Antipsychotic Drugs: A Selective Review (1996) (73)
Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain (2012) (73)
Concordance of atopic and affective disorders. (1981) (72)
Duration of a clozapine trial in neuroleptic-resistant schizophrenia. (1989) (72)
Neuromuscular dysfunction in schizophrenia. (1976) (72)
Positive, Negative, and Disorganisation Factors from the Schedule for Affective Disorders and Schizophrenia and the Present State Examination (1993) (72)
Comparison of in vivo and in vitro glucocorticoid sensitivity in depression: Relationship to the dexamethasone suppression test (1988) (72)
Genetic control of serotonin uptake in blood platelets: A twin study (1988) (71)
3H-imipramine binding in the frontal cortex of suicides (1989) (71)
Autoimmunity in depression: increased antiphospholipid autoantibodies (1993) (70)
Clozapine: New research on efficacy and mechanism of action (1989) (70)
Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant (2010) (70)
A model of smooth pursuit performance illustrates the relationship between gain, catch-up saccade rate, and catch-up saccade amplitude in normal controls and patients with schizophrenia (1991) (70)
Effect of clozapine in severe tardive dyskinesia: a case report. (1984) (70)
Pathway-based analysis of GWAS datasets: effective but caution required. (2011) (70)
Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response (2008) (69)
Brain Noradrenergic Receptors in Major Depression and Schizophrenia (1999) (69)
Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients (1991) (69)
Olanzapine: A New Atypical Antipsychotic Drug (1996) (69)
Nicotine Impairs Spatial Working Memory while Leaving Spatial Attention Intact (2000) (69)
Reduced Glutamatergic Currents and Dendritic Branching of Layer 5 Pyramidal Cells Contribute to Medial Prefrontal Cortex Deactivation in a Rat Model of Neuropathic Pain (2016) (69)
Recent advances in the pharmacotherapy of schxzophrenia (1994) (68)
Clozapine increases rat serum prolactin levels. (1975) (68)
Cortisol determination and the dexamethasone suppression test. A review. (1983) (67)
The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain (2012) (67)
Comparison of the effects of substituted benzamides and standard neuroleptics on the binding of 3H-spiroperidol in the rat pituitary and striatum with in vivo effects on rat prolactin secretion. (1979) (66)
Systematic analysis of dopamine receptor genes (DRD1–DRD5) in antipsychotic-induced weight gain (2010) (66)
Effect of serotonin precursors and serotonin agonists on plasma hormone levels. (1982) (66)
Antagonism of serotonin receptor mediated neuroendocrine and temperature responses by atypical neuroleptics in the rat. (1988) (66)
Neurotensin activates tuberoinfundibular dopamine neurons and increases serum corticosterone concentrations in the rat. (1989) (66)
A blind, controlled study of occipital cerebral asymmetry in schizophrenia (1983) (66)
Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. (2000) (66)
Relationships between increased haptoglobin plasma levels and activation of cell-mediated immunity in depression (1993) (65)
Effects of long-term cigarette smoking on the human locus coeruleus. (2001) (64)
Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5‐HT)2A and DA D2 antagonism and 5‐HT1A partial agonism (2014) (64)
Cycloid Psychoses: Diagnosis and Heuristic Value (1982) (64)
Neuroleptic-induced prolactin level elevation and breast cancer: an emerging clinical issue. (1978) (64)
Adverse events related to olanzapine. (2000) (64)
759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. (2002) (63)
Incidence of Z band streaming and myofibrillar disruptions in skeletal muscle from healthy young people (1976) (63)
A Biochemical and Neuroendocrine Study of the Serotonergic System in Depression (1986) (63)
Neuroendocrine responses to serotonergic agents in alcoholics (1991) (63)
Serotonin uptake and imipramine binding in the blood platelets of obsessive-compulsive disorder patients (1991) (63)
Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes. (2010) (63)
Selective Increases in Phosphoinositide Signaling Activity and G Protein Levels in Postmortem Brain from Subjects with Schizophrenia or Alcohol Dependence (1998) (63)
Effects of serotonin precursors on the negative feedback effects of glucocorticoids on hypothalamic-pituitary-adrenal axis function in depression (1995) (62)
Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine. (1997) (62)
ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens (2005) (62)
A modified assay method for determining serotonin uptake in human platelets. (1981) (61)
Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes (2017) (61)
Suggestive association between the C825T polymorphism of the G-protein β3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia (2005) (61)
Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens (2002) (61)
Association study of dopamine D3 receptor gene and schizophrenia. (1995) (60)
Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response (1983) (60)
Frequency analysis of large CAG/CTG trinucleotide repeats in schizophrenia and bipolar affective disorder. (1996) (60)
Phencyclidine-induced ipsilateral rotation in rats with unilateral 6-hydroxydopamine-induced lesions of the substantia nigra. (1979) (60)
Black-white differences in serum creatine phosphokinase (CPK) activity. (1974) (60)
DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release (2001) (59)
Phencyclidine as an indirect dopamine agonist [proceedings]. (1980) (59)
Treatment of schizoaffective disorders. (1984) (59)
Adverse effects of the atypical antipsychotics (1998) (59)
Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex (2006) (59)
Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. (2013) (58)
Pindolol pretreatment blocks stimulation by meta-chlorophenylpiperazine of prolactin but not cortisol secretion in normal men (1995) (58)
Factors affecting determination of platelet monoamine oxidase activity. (1980) (58)
Effect of 3,4‐Methylenedioxymethamphetamine on 3,4‐Dihydroxyphenylalanine Accumulation in the Striatum and Nucleus Accumbens (1990) (58)
D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs (1995) (58)
Platelet serotonin levels in schizophrenia: relationship to race and psychopathology. (1983) (58)
Psychoimmune investigation in obsessive-compulsive disorder: assays of plasma transferrin, IL-2 and IL-6 receptor, and IL-1 beta and IL-6 concentrations. (1994) (58)
Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea (1991) (57)
Amperozide, a Novel Antipsychotic Drug, Inhibits the Ability of d‐Amphetamine to Increase Dopamine Release In Vivo in Rat Striatum and Nucleus Accumbens (1992) (57)
Association study between the dopamine D4 receptor gene and schizophrenia. (1995) (57)
Cognitive Factors in Schizophrenia: Causes, Impact, and Treatment (2004) (57)
Serum-Enzyme Changes in Newly Admitted Psychiatric Patients: Part I (1969) (57)
Massive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message? (2000) (56)
5-HT2A receptor stimulation by DOI, a 5-HT2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens (2003) (56)
Regional cerebral blood flow in unipolar depression measured with Tc-99m-HMPAO single photon emission computed tomography: Negative findings (1993) (56)
The effect of chronic clozapine and haloperidol on basal dopamine release and metabolism in rat striatum and nucleus accumbens studied by in vivo microdialysis. (1990) (56)
5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus (2007) (56)
Natural killer cell activity in major depression: Relation to circulating natural killer cells, cellular indices of the immune response, and depressive phenomenology (1994) (56)
Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment (2007) (56)
Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant (1979) (56)
Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene (2012) (56)
Clozapine-induced myoclonus and generalized seizures (1996) (56)
Oxidative stress in tardive dyskinesia: Genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes (2010) (55)
The relevance of the in- versus outpatient status for studies on HPA-axis in depression: Spontaneous hypercortisolism is a feature of major depressed inpatients and not of major depression per se (1994) (55)
SLV313 (1-(2,3-Dihydro-Benzo[1,4]Dioxin-5-yl)-4- [5-(4-Fluoro-Phenyl)-Pyridin-3-ylmethyl]-Piperazine Monohydrochloride): A Novel Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist Potential Antipsychotic Drug (2007) (55)
Muscle abnormalities in acute psychoses. (1970) (54)
Low-dose loxapine in the treatment of schizophrenia: is it more effective and more "atypical" than standard-dose loxapine? (1999) (54)
Comparison of Ketamine and Thiopental in Healthy Volunteers: Effects on Mental Status, Mood, and Personality (1984) (54)
Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs (1996) (54)
Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats (2011) (53)
Suicide in schizophrenia, clozapine, and adoption of evidence-based medicine. (2005) (53)
Altered responses to serotonergic agents in Fawn-Hooded rats (1985) (53)
The brain‐derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia (2015) (53)
Reducing the risk for suicide in schizophrenia and affective disorders. (2003) (53)
Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma (2019) (53)
Effect of antidepressants, lithium and electroconvulsive treatment on rat serum prolactin levels (1981) (53)
The Blunted Plasma Cortisol Response to Apomorphine and Its Relationship to Treatment Response in Patients with Schizophrenia (2001) (53)
Asenapine Increases Dopamine, Norepinephrine, and Acetylcholine Efflux in the Rat Medial Prefrontal Cortex and Hippocampus (2008) (52)
R(+)-8-OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced serotonin and dopamine release in rat medial prefrontal cortex (1996) (52)
Decreased dopamine beta-hydroxylase activity in unipolar geriatric delusional depression (1999) (51)
Association of a Functional Polymorphism in Neuropeptide Y With Antipsychotic-Induced Weight Gain in Schizophrenia Patients (2013) (51)
Smooth pursuit performance in patients with affective disorders or schizophrenia and normal controls: analysis with specific oculomotor measures, RMS error and qualitative ratings (1995) (51)
Neuropsychologic Deficits in Schizophrenia (1996) (51)
Dexamethasone suppression test abnormalities in multiple sclerosis (1987) (51)
Behavioral and endocrine responses of schizophrenic patients to TRH (protirelin). (1979) (50)
Association of the alpha 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. (2009) (50)
Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia (2009) (50)
The hypothalamic-pituitary-adrenal axis in depression. (1987) (50)
A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. (2006) (50)
Family and case–control association study of the tumor necrosis factor-alpha (TNF-α) gene with schizophrenia and response to antipsychotic medication (2006) (50)
Effects of clozapine on sleep measures and sleep-associated changes in growth hormone and cortisol in patients with schizophrenia (2001) (50)
Commentary: Defining Treatment Refractoriness in Schizophrenia (1990) (49)
Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics. (2001) (49)
Determinants of work outcome in schizophrenia and schizoaffective disorder: Role of cognitive function (2009) (49)
Lithium potentiation of antidepressant treatment. (1984) (49)
MECHANISM OF ACTION OF ATYPICAL ANTIPSYCHOTIC DRUGS (2002) (49)
A Novel Role for Glyceraldehyde-3-Phosphate Dehydrogenase and Monoamine Oxidase B Cascade in Ethanol-Induced Cellular Damage (2010) (49)
Drug treatment in delusional depression (1980) (49)
Immunoendocrine aspects of major depression. Relationships between plasma interleukin-6 and soluble interleukin-2 receptor, prolactin and cortisol. (1995) (49)
Neurokinin-1 receptors are decreased in major depressive disorder (2002) (49)
Effect of typical antipsychotic medications and clozapine on smooth pursuit performance in patients with schizophrenia (1992) (49)
Hormones, dopamine receptors and schizophrenia (1981) (48)
Serum creatine phosphokinase in schizophrenia. (1976) (48)
Variants in the oxytocin gene and risk for schizophrenia (2010) (48)
The concentration of arginine vasopressin in pituitary stalk plasma of the rat after adrenalectomy or morphine. (1986) (48)
Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response (2007) (48)
Differential expression of synaptosome-associated protein 25 kDa [SNAP-25] in hippocampi of neonatal mice following exposure to human influenza virus in utero (1998) (48)
Mean serum creatine kinase activity in patients with functional psychoses. (1980) (48)
Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors. (1998) (48)
The Effect of Streptozotocin-Induced Diabetes on Dopamine2, Serotonin1A and Serotonin2A Receptors in the Rat Brain (1997) (47)
Immunoendocrine aspects of major depression (1995) (47)
N,N-dimethylated indoleamines in blood. (1971) (47)
Clinical development of atypical antipsychotics: research design and evaluation. Collaborative Working Group on Clinical Trial Evaluations. (1998) (47)
5-HT1A and 5-HT2A receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex (2002) (47)
New Trends in the Treatment of Schizophrenia. (2017) (46)
Effect of clozapine on psychogenic polydipsia in chronic schizophrenia. (1991) (46)
The Effect of Short-Term Electroconvulsive Treatment Plus Neuroleptics in Treatment-Resistant Schizophrenia and Schizoaffective Disorder. (1993) (46)
Effect of repeated administration of phencyclidine on spatial performance in an eight-arm radial maze with delay in rats and mice (2003) (46)
The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens (2014) (46)
Immunoglobulin studies in patients with psychiatric diseases. (1985) (46)
Valproic acid potentiates both typical and atypical antipsychotic-induced prefrontal cortical dopamine release (2005) (46)
Cognitive Functioning Predicts Outpatient Service Utilization in Schizophrenia (2004) (46)
Voluntary movement dysfunction in schizophrenics (1989) (46)
Dissecting the Functional Consequences of De Novo DNA Methylation Dynamics in Human Motor Neuron Differentiation and Physiology. (2018) (45)
Effect of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol or thioridazine. (1994) (45)
Suicide in Schizophrenia: The Effect of Clozapine (1995) (45)
Clozapine Acts as an Agonist at Serotonin 2A Receptors to Counter MK-801-Induced Behaviors through a βArrestin2-Independent Activation of Akt (2014) (45)
Role of Clozapine in Treatment-Resistant Schizophrenia (2010) (45)
The pharmacoeconomics of clozapine: a review. (1994) (45)
HTR2C haplotypes and antipsychotics‐induced weight gain: X‐linked multimarker analysis (2007) (45)
β-Adrenergic receptor binding in frontal cortex of suicide victims (1991) (45)
The relationship of demographic, clinical, and outcome variables to neuroleptic treatment requirements. (1980) (44)
The Clinical Picture of Bipolar Affective Disorder in its Depressed Phase (1982) (44)
Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. (2010) (44)
Dopaminergic and serotonergic effects of clozapine. Implications for a unique clinical profile. (1992) (44)
Saccadic intrusions into smooth pursuit in patients with schizophrenia or affective disorder and normal controls (1992) (44)
Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis (2016) (44)
Haptoglobin phenotypes and gene frequencies in unipolar major depression. (1994) (43)
GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice (2016) (43)
Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease: A high potency effect of clozapine (1995) (43)
Effects of phencyclidine and methylphenidate on d-amphetamine-induced behaviors in reserpine pretreated rats (1980) (43)
Effects of enkephalin in analogues on prolactin release in the rat. (1978) (43)
Psychological and behavioural effects of interferons (2000) (43)
Laterality and 3H-imipramine binding: Studies in the frontal cortex of normal controls and suicide victims (1991) (43)
Functional magnetic resonance imaging in schizophrenia: initial methodology and evaluation of the motor cortex (1997) (43)
Lithium differs from anticonvulsant mood stabilizers in prefrontal cortical and accumbal dopamine release: Role of 5-HT1A receptor agonism (2005) (43)
Reduction of serotonin-2 receptors in rat cerebral cortex after subchronic administration of imipramine, chlorpromazine, and the combination thereof. (1984) (42)
Serotonin but not norepinephrine-induced calcium mobilization of platelets is enhanced in affective disorders (2005) (42)
Subterminal motor nerve abnormalities in psychotic patients (1974) (42)
Clozapine in treatment-refractory mood disorders. (1994) (42)
Risperidone in treatment of choreoathetosis of Huntington's disease. (1997) (42)
Platelet monoamine oxidase and plasma amine oxidase in psychiatric patients. (1980) (42)
Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era (2006) (42)
Selective cross-tolerance to 5-HT1A and 5-HT2 receptor-mediated temperature and corticosterone responses (1989) (42)
The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia (2003) (42)
The nosology of schizoaffective psychosis. (1983) (42)
Cognitive effects of olanzapine treatment in schizophrenia. (2004) (41)
A comparison of the effects of neuroleptics on phencyclidine-induced behaviors in the rat. (1981) (41)
Plasma Clozapine and Desmethylclozapine Levels in Clozapine-Induced Agranulocytosis (1994) (41)
Serotonin2 receptor binding in blood platelets of schizophrenic patients (1993) (41)
A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. (2011) (41)
Relation of exercise to MHPG excretion in normal subjects. (1973) (41)
Negative symptoms and platelet monoamine oxidase activity in male schizophrenic patients (1984) (41)
PET measurement of neuroreceptor occupancy by typical and atypical neuroleptics. (1996) (40)
Atypical antipsychotic drugs improve cognition in schizophrenia (2003) (40)
Clinical processes and central dopaminergic activity in psychotic disorders. (1980) (40)
5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux (2012) (40)
Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment (2006) (39)
Effect of lithium carbonate on serotonin uptake in blood platelets of patients with affective disorders. (1983) (39)
Dopamine antagonism by thioridazine in schizophrenia. (1975) (39)
Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine (1996) (39)
Effects of subchronic treatment with valproate on l-5-HTP-induced cortisol responses in mania: evidence for increased central serotonergic neurotransmission (1997) (39)
The brief psychiatric rating scale: effect of scaling system on clinical response assessment. (1994) (38)
Decreased plasma tryptophan and tryptophan/large neutral amino acid ratio in patients with neuroleptic-resistant schizophrenia: Relationship to plasma cortisol concentration (2011) (38)
Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia. (2005) (38)
D1 receptor agonists reverse the subchronic phencyclidine (PCP)-induced novel object recognition (NOR) deficit in female rats (2013) (38)
Histochemical abnormalities of skeletal muscle in acutely psychotic patients. II. (1970) (38)
The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo (1992) (37)
Relationship between smooth pursuit eye-tracking and cognitive performance in schizophrenia (1995) (37)
The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. (2000) (37)
Physiologic abnormalities of the neuromuscular system in schizophrenia. (1977) (37)
Negative symptoms in schizophrenia: a target for new drug development. (1989) (37)
Effect of buspirone on prolactin secretion is not mediated by 5-HT-1a receptor stimulation. (1992) (37)
Imipramine binding in subpopulations of normal human blood platelets. (1984) (37)
Plasma creatine phosphokinase activity, hypothermia, and stress. (1971) (37)
Platelet MAO activity in hallucinating and paranoid schizophrenics: A review and meta-analysis (1988) (37)
Interpreting the Efficacy Findings in the CATIE Study: What Clinicians Should Know (2006) (37)
Effects of pirenperone and ketanserin on rat prolactin secretion in vivo and in vitro. (1983) (37)
Atypical antipsychotic drugs and organization of long-term semantic memory: multidimensional scaling and cluster analyses of category fluency performance in schizophrenia. (2006) (37)
The atypical antipsychotic drug amperozide enhances rat cortical and striatal dopamine efflux. (1993) (37)
The Novel Antipsychotic Drug Lurasidone Enhances N-Methyl-d-aspartate Receptor-Mediated Synaptic Responses (2012) (36)
Genome-wide association study on antipsychotic-induced weight gain in the CATIE sample (2015) (36)
Neuropeptide Y in Frontal Cortex Is Not Altered in Major Depression (1995) (36)
Comparison of platelet count and platelet protein methods for determination of platelet MAO activity. (1979) (36)
Serotonin uptake by blood platelets of schizophrenic patients (1982) (36)
5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice (2017) (36)
Prevention of the Phencyclidine-Induced Impairment in Novel Object Recognition in Female Rats by Co-Administration of Lurasidone or Tandospirone, a 5-HT1A Partial Agonist (2012) (36)
Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response. (2010) (36)
No evidence for association of dopamine D2 receptor variant (Ser311/Cys311) with major psychosis. (1996) (36)
A comparison of CT findings in acute and chronic ward schizophrenics (1986) (35)
Dopamine receptors and average clinical doses. (1976) (35)
Multiple reciprocal relationships between in vivo cellular immunity and hypothalamic–pituitary–adrenal axis in depression (1994) (35)
Serotonergic measures in suicide brain: The concentration of 5-HIAA, HVA, and tryptophan in frontal cortex of suicide victims (1992) (35)
Effect of antidepressants on neuroendocrine axis in humans. (1982) (35)
Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia (2006) (35)
The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients. (2004) (35)
Clozapine: Mechanism of Action in Relation to its Clinical Advantages (1990) (35)
A longitudinal study of thought disorder in manic patients. (1986) (35)
The human platelet as a model for the dopaminergic neuron: Kinetic and pharmacologic properties and the role of amine storage granules (1978) (35)
Decreased platelet alpha-2 adrenoceptor density in major depression: effects of tricyclic antidepressants and fluoxetine (1999) (35)
Biochemical studies in schizophrenia. (1976) (35)
Sleep disorders and anxiety as symptom profiles of sympathoadrenal system hyperactivity in major depression. (1993) (35)
Behavioral effects of chronic phencyclidine administration in rats (2004) (35)
Effects of divalproex and atypical antipsychotic drugs on dopamine and acetylcholine efflux in rat hippocampus and prefrontal cortex (2006) (35)
Dopaminergic effects of phencyclidine in rats with nigrostriatal lesions. (1975) (35)
Prolonged psychotic relapse after abrupt clozapine withdrawal. (1993) (34)
Antipsychotic drugs in bipolar disorder. (2003) (34)
Plasma enzymatic activity after exercise. Study of psychiatric patients and their relatives. (1970) (34)
Subchronic phencyclidine treatment in adult mice increases GABAergic transmission and LTP threshold in the hippocampus (2016) (34)
The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: A randomized, double-blind, placebo-controlled trial (2011) (34)
Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients (2009) (34)
Association of Sult4A1 SNPs with psychopathology and cognition in patients with schizophrenia or schizoaffective disorder (2008) (34)
Association study of polymorphisms in Insulin Induced Gene 2 (INSIG2) with antipsychotic‐induced weight gain in European and African‐American schizophrenia patients (2010) (34)
Effect of clozapine on psychotic depression and parkinsonism. (1991) (34)
Efficacy vs. effectiveness in psychiatric research. (1998) (34)
Substance abuse and clozapine treatment. (1994) (34)
Evidence that the medial and dorsal raphe nuclei mediate serotonergically-induced increases in prolactin release from the pituitary (1984) (33)
Dopamine autoreceptor stimulation: Clinical significance (1982) (33)
Effect of gepirone and ipsapirone on the stimulated and unstimulated secretion of prolactin in the rat. (1989) (33)
Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: Replication and exploration (2012) (33)
Effect of amperozide on rat cortical 5-HT2 and striatal and limbic dopamine D2 receptor occupancy: implications for antipsychotic action. (1992) (33)
JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: a review of its behavioural properties. (1997) (33)
Effect of neuroleptic drugs on platelet monoamine oxidase in psychiatric patients. (1982) (33)
The role of genetic variation across IL-1β, IL-2, IL-6, and BDNF in antipsychotic-induced weight gain (2015) (33)
Effect of incubation in human plasma on electrophoretic mobility of brain-type creatine phosphokinase. (1976) (33)
Serotonin 1A receptors in memory function. (2004) (33)
Plasma Clozapine Levels and the Treatment of L-DOPA-Induced Psychosis in Parkinson's Disease (1995) (33)
Novel approaches to the pharmacotherapy of schizophrenia (1986) (33)
Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: Relation to neuroleptic resistance (1997) (32)
DRUG DISCOVERY AND EVALUATION (2002) (32)
The neurotensin analog NT69L enhances medial prefrontal cortical dopamine and acetylcholine efflux: Potentiation of risperidone-, but not haloperidol-, induced dopamine efflux (2007) (32)
AC260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus. (2007) (32)
Quantitative distribution of monoamine oxidase A in brainstem monoamine nuclei is normal in major depression (1999) (32)
Long-term effects of neuroleptic drugs on the neuroendocrine system. (1985) (32)
Motoneuron excitability in psychiatric patients. (1977) (32)
An atypical compound by any other name is still a.... (2000) (32)
Melperone and clozapine: neuroendocrine effects of atypical neuroleptic drugs (1989) (32)
Clozapine withdrawal: serotonergic or dopaminergic mechanisms? (1997) (32)
Assessing the effects of atypical antipsychotics on negative symptoms. Collaborative Working Group on Clinical Trial Evaluations. (1998) (32)
Serotonin and Mood: Neuroendocrine Aspects (1988) (32)
Skeletal muscle necrosis following membrane-active drugs plus serotonin (1976) (31)
Serotonin uptake in blood platelets and the dexamethasone suppression test in depressed patients (1983) (31)
The Evolution of Treatment Resistance: Biologic Implications (1998) (31)
A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia (2014) (31)
Disruption of myofibrils in the skeletal muscle of psychotic patients. (1970) (31)
Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response. (2016) (31)
New drugs for the treatment of schizophrenia. (1993) (31)
The prognostic relevance of delusions in depression: a follow-up study. (1987) (30)
Rod (nemaline) bodies in the skeletal muscle of an acute schizophrenic patient (1973) (30)
Lateral ventricular size and drug-induced parkinsonism (1983) (30)
Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations. (1998) (30)
Discriminative stimulus properties of 1.25 and 5.0 mg/kg doses of clozapine in rats: examination of the role of dopamine, serotonin, and muscarinic receptor mechanisms (2004) (30)
Effect of pindolol pretreatment on MK-212-induced plasma cortisol and prolactin responses in normal men (1995) (30)
Central core fibers in an acutely psychotic patient. Evidence for a neurogenic basis for the muscle abnormalities in the acute psychoses. (1972) (30)
Serum Creatine Phosphokinase Activity in Newly Admitted Psychiatric Patients: Part II (1971) (30)
A comparison of the effects of anti-psychotic drugs on pituitary, striatal and limbic system post-synaptic dopamine receptors. (1978) (30)
Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain. (2012) (30)
Neuroendocrine measures of dopaminergic function in chronic cocaine users (1990) (30)
Activation of tuberoinfundibular dopamine neurons following the acute administration of atypical antipsychotics. (1989) (29)
Apomorphine does not reverse reduced basal dopamine release in rat striatum and nucleus accumbens after chronic haloperidol treatment (1990) (29)
The catechol-O-methyl-transferase gene in tardive dyskinesia (2010) (29)
Clozapine pretreatment modifies haloperidol-elicited forebrain Fos induction: a regionally-specific double dissociation (1999) (29)
A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia (2010) (29)
A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens (2003) (29)
Effects of Desmethylclozapine on Fos Protein Expression in the Forebrain: In Vivo Biological Activity of the Clozapine Metabolite (1998) (29)
Respiratory Microbial Co-infection With SARS-CoV-2 (2020) (29)
Morphine or capsaicin administration alters the secretion of beta-endorphin into the hypophysial portal vasculature of the rat. (1986) (29)
Seasonal variation of imipramine binding in the blood platelets of normal controls and depressed patients (1988) (29)
Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances. (2014) (28)
Exome sequence analysis of Finnish patients with clozapine-induced agranulocytosis (2014) (28)
Skeletal muscle MAO activity in the major psychoses. Relationship with platelet and plasma MAO activities. (1980) (28)
No association of the T102C polymorphism of the serotonin 2A receptor gene (HTR2A) with suicidality in schizophrenia (2004) (28)
A Hypothesis-Driven Association Study of 28 Nuclear-Encoded Mitochondrial Genes with Antipsychotic-Induced Weight Gain in Schizophrenia (2014) (28)
Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia (2008) (28)
Effects of corticotrophin-releasing factor receptor 1 antagonists on amyloid-β and behavior in Tg2576 mice (2014) (28)
Transcultural differences in suicide attempters: Analysis on a high-risk population of patients with schizophrenia or schizoaffective disorder (2007) (28)
Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study (2012) (28)
Prolactin response to morphine in depression (1984) (28)
Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. (1998) (28)
The use of clozapine in borderline-intellectual-functioning and mentally retarded schizophrenic patients. (1994) (28)
Differential effects of chronic imipramine and fluoxetine on basal and amphetamine-induced extracellular dopamine levels in rat nucleus accumbens. (1998) (28)
PLATELET 3H-IMIPRAMINE BINDING AND PLATELET 5-HT UPTAKE IN AFFECTIVE DISORDERS AND SCHIZOPHRENIA (1984) (27)
A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine. (2004) (27)
Involvement of Cholinergic System in Hyperactivity in Dopamine-Deficient Mice (2014) (27)
Effect of buspirone on prolactin and growth hormone secretion in laboratory rodents and man. (1982) (27)
Pharmacotherapy of cognition in schizophrenia (2015) (27)
Genetic variation in CYP3A43 is associated with response to antipsychotic medication (2014) (27)
[Refractory schizophrenia]. (2007) (27)
Increased prefrontal sulcal prominence in relatively young patients with unipolar major depression (1996) (27)
The alpha-7 nicotinic receptor partial agonist/5-HT3 antagonist RG3487 enhances cortical and hippocampal dopamine and acetylcholine release (2013) (27)
Serum dopamine-beta-hydroxylase activity in schizophrenia. (1980) (27)
Platelet monoamine oxidase activity and substrate preferences in schizophrenic patients. (1974) (27)
Behavioral changes in rats after acute, chronic and repeated administration of interleukin-1beta: relevance for affective disorders. (2003) (26)
Evidence for the existence of major depression with and without anxiety features. (1994) (26)
Clinical efficacy of clozapine in the treatment of schizophrenia. (1991) (26)
The FOCIS international survey on psychiatrists' opinions on cognition in schizophrenia (2005) (26)
Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden (2007) (26)
Effect of adrenalectomy and corticosterone on [3H]imipramine binding in rat blood platelets and brain. (1986) (26)
Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement (2015) (26)
Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia (2011) (26)
5-HT(2A) and 5-HT(2C) receptor stimulation are differentially involved in the cortical dopamine efflux-Studied in 5-HT(2A) and 5-HT(2C) genetic mutant mice. (2011) (26)
Effect of (des-tyr)-gamma-endorphin in schizophrenia (1982) (26)
5-HT1A receptor dysfunction in female patients with schizophrenia (2001) (26)
Focus on the metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences? (2005) (25)
Documenting an episode of psychiatric illness: need for multiple information sources, multiple raters, and narrative. (1982) (25)
Acetylcholinesterase Inhibitors Are Neither Necessary nor Desirable for Microdialysis Studies of Brain Acetylcholine (2000) (25)
Azapirone 5-HT1A receptor partial agonist treatment for major depressive disorder: systematic review and meta-analysis (2013) (25)
The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response (2011) (25)
Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: Cognitive impairment and clozapine treatment (2010) (25)
Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine (1997) (25)
Effect of desipramine treatment on 3H-imipramine binding in the blood platelets of depressed patients (1988) (25)
Biological studies of schizoaffective disorders. (1984) (25)
Relationship of auditory hallucinations and paranoia to platelet MAO activity in schizophrenics: Sex and race interactions (1987) (24)
What is schizophrenia? (1982) (24)
Blonanserin reverses the phencyclidine (PCP)-induced impairment in novel object recognition (NOR) in rats: Role of indirect 5-HT1A partial agonism (2013) (24)
Application of pharmacogenetics to psychotic disorders: the first consensus conference. The Consensus Group for Outcome Measures in Psychoses for Pharmacological Studies. (1999) (24)
Effect of protein concentration on kinetic constants (K d and B max) of 3H-Imipramine binding in blood platelets (1985) (24)
Skeletal muscle abnormalities in patients with affective disorders. (1973) (24)
A genetic locus in 7p12.2 associated with treatment resistant schizophrenia (2014) (24)
Effect of the serotonin agonist, MK-212, on body temperature in schizophrenia (1992) (24)
Differential patterns of neuropsychological deficit in psychiatric disorders. (1988) (24)
Platelet imipramine binding in depressed children and adolescents. (1992) (24)
Effect of yohimbine on rat prolactin secretion. (1983) (23)
Plasma dopamine-beta-hydroxylase in depressed patients. (1982) (23)
Serotonin uptake in the blood platelets of Alzheimer's disease patients (1991) (23)
Treatment of delusional disorders with clozapine [3] (1994) (23)
Serum prolactin response to chlorpromazine and psychopathology in schizophrenics: Implications for the dopamine hypothesis (1983) (23)
Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis. (2013) (23)
Effect of 3,4-methylenedioxymethamphetamine on [3H]paroxetine binding in the frontal cortex and blood platelets of rats. (1991) (23)
The Effect of Clozapine and Other Atypical Antipsychotic Drugs on Negative Symptoms (1991) (23)
Degeneration and regeneration of motor neurons in psychotic patients. (1979) (23)
Serotonin (5-HT)1A receptor agonism and 5-HT7 receptor antagonism ameliorate the subchronic phencyclidine-induced deficit in executive functioning in mice (2016) (23)
Gamma-Aminobutyric Acidergic Projections From the Dorsal Raphe to the Nucleus Accumbens Are Regulated by Neuromedin U (2016) (23)
Evidence for a SULT4A1 haplotype correlating with baseline psychopathology and atypical antipsychotic response. (2011) (23)
Neuroleptic malignant syndrome without neuroleptics. (1990) (23)
Vascular and extravascular immunoreactivity for intercellular adhesion molecule 1 in the orbitofrontal cortex of subjects with major depression: age-dependent changes. (2011) (23)
5-HT 2A receptor stimulation by DOI, a 5-HT 2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. (2003) (23)
Quantitative histochemical evaluation of normal human skeletal muscle (1976) (23)
Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients (2010) (22)
CLOZAPINE-LIKE DRUGS (1980) (22)
Differential Effects of M1 and 5-Hydroxytryptamine1A Receptors on Atypical Antipsychotic Drug-Induced Dopamine Efflux in the Medial Prefrontal Cortex (2009) (22)
Radioimmunoassay for MM and BB isoenzymes of creatine kinase substantiated by clinical application. (1977) (22)
Psychiatric Manifestations of Olivo-Ponto-Cerebellar Atrophy and Treatment with Clozapine (1993) (22)
Interaction of (+)- and (-)-3-PPP with the dopamine receptor in the anterior pituitary gland. (1984) (22)
Further characterization of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in C57BL/6 mice: role of 5-HT2A serotonergic and α1 adrenergic antagonism (2009) (22)
Neuroendocrine effects of buspirone in patients with generalized anxiety disorder. (1986) (22)
Synthesis and biological evaluation of p-bromospiperone as potential neuroleptic drug. (1980) (22)
Effect of pindolol on thel-5-htp-induced increase in plasma prolactin and cortisol concentrations in man (1994) (22)
Fat Mass- and Obesity-Associated (FTO) Gene and Antipsychotic-Induced Weight Gain: An Association Study (2014) (22)
Association of orexin receptor polymorphisms with antipsychotic-induced weight gain (2016) (22)
Effective adjunctive use of tandospirone with perospirone for enhancing verbal memory and quality of life in schizophrenia (2007) (22)
Action of atypical antipsychotics. (2002) (22)
Sleep disturbance and serum CPK activity in acute psychosis. (1970) (21)
Influence of bupropion HCl (Wellbatrin), a novel antidepressant, on plasma levels of prolactin and growth hormone in man and rat. (1979) (21)
The neurobiology of schizophrenia (1991) (21)
5-Hydroxytryptophan-induced cortisol response and CSF 5-HIAA in depressed patients. (1987) (21)
Validity of subtyping psychotic depression: examination of phenomenology and demographic characteristics. (1988) (21)
NK3 receptor antagonists for the treatment of schizophrenia (2006) (21)
Descriptive studies of H-reflex recovery curves in psychiatric patients (1980) (21)
Circadian rhythm of serotonin uptake in the blood platelets of normal controls. (1984) (21)
Comparative effectiveness research for antipsychotic medications: how much is enough? (2009) (21)
Factors affecting stability of isozymes of creatine phosphokinase. (1979) (21)
Effects of isometric exercise on serum creatine phosphokinase activity. (1976) (21)
Combined serotonin (5-HT)1A agonism, 5-HT2A and dopamine D2 receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats (2015) (21)
Muscle abnormalities in psychotic patients. II. Serum CPK activity, fiber abnormalities, and branching and sprouting of subterminal nerves. (1974) (21)
Human platelet alpha 2-adrenergic receptors: labeling with 3H-yohimbine, a selective antagonist ligand. (1981) (21)
Nicotinic receptors and lurasidone-mediated reversal of phencyclidine-induced deficit in novel object recognition (2016) (20)
Replicated association of the NR4A3 gene with smoking behaviour in schizophrenia and in bipolar disorder (2010) (20)
Association study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesia (2005) (20)
Replication of rs300774, a genetic biomarker near ACP1, associated with suicide attempts in patients with schizophrenia: Relation to brain cholesterol biosynthesis. (2017) (20)
Reducing Suicide Risk in Schizophrenia (2000) (20)
Dopamine D4 receptor stimulation contributes to novel object recognition: Relevance to cognitive impairment in schizophrenia (2017) (20)
The allosteric dopamine D1 receptor potentiator, DETQ, ameliorates subchronic phencyclidine-induced object recognition memory deficits and enhances cortical acetylcholine efflux in male humanized D1 receptor knock-in mice (2019) (20)
Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine. (2008) (20)
Serum dopamine-β-hydroxylase activity and lateral ventricular size in affective disorders and schizophrenia (1984) (20)
Effect of the placebo control condition in neuroendocrine challenge studies (1994) (20)
Effects of meta-chlorophenylpiperazine on neuroendocrine and behavioral responses in male schizophrenic patients and normal volunteers (1996) (20)
New insights into schizophrenia through atypical antipsychotic drugs *1Comments on ?the current status of the dopamine hypothesis of schizophrenia? (1988) (20)
Blunted oral body temperature response to MK-212 in cocaine addicts. (1994) (20)
Investigating association of four gene regions (GABRB3, MAOB, PAH, and SLC6A4) with five symptoms in schizophrenia (2012) (20)
Attention Must Be Paid: The Association of Plasma Clozapine/NDMC Ratio With Working Memory. (2015) (19)
Effects of lithium on behaviour induced by phencyclidine and amphetamine in rats (1982) (19)
Lateral ventricular size in the psychoses: relation to psychopathology and therapeutic and adverse response to medications. (1983) (19)
Δ9-tetrahydrocannabinol (Δ9-THC) administration after neonatal exposure to phencyclidine potentiates schizophrenia-related behavioral phenotypes in mice (2017) (19)
Variability in Response to Clozapine: Potential Role of Cytochrome P450 1A2 and the Dopamine D4 Receptor Gene (1999) (19)
Exploratory study on association of genetic variation in TBC1D1 with antipsychotic‐induced weight gain (2013) (19)
The role of the ITIH3 rs2535629 variant in antipsychotic response (2016) (19)
the dopamine hypothesis of schizophrenia (1976) (19)
Psychosis of Parkinson's disease: serotonin 2A receptor inverse agonists as potential therapeutics. (2003) (19)
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations. (1998) (19)
Association Study of GABAA &agr;2 Receptor Subunit Gene Variants in Antipsychotic-Associated Weight Gain (2015) (19)
Effects of age on spontaneous cortisolaemia of normal volunteers and depressed patients (1994) (19)
Treatment of special populations with the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. (1998) (19)
Motor neuron branching patterns in psychotic patients. (1981) (18)
Ventricular size and psychosis in affective disorder. (1983) (18)
Pathologic effect of phencyclidine and restraint on rat skeletal muscle structure: prevention by prior denervation. (1974) (18)
Melperone in the treatment of neuroleptic-resistant schizophrenia (2001) (18)
Neurochemical arguments for the use of dopamine D4 receptor stimulation to improve cognitive impairment associated with schizophrenia (2017) (18)
P.2.067 Ziprasidone: Efficacy in the prevention of relapse and in the long-term treatment of negative symptoms of chronic schizophrenia (1997) (18)
RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia (2017) (18)
5-HT1A parital agonism and 5-HT7 antagonism restore episodic memory in subchronic phencyclidine-treated mice: role of brain glutamate, dopamine, acetylcholine and GABA (2018) (18)
Enantioselective Syntheses of Heteroyohimbine Natural Products: A Unified Approach through Cooperative Catalysis. (2015) (18)
The effect of the atypical antipsychotic drug, amperozide, on carrier-mediated striatal dopamine release measured in vivo. (1992) (18)
Abnormal serotonergic stimulation of cortisol production in obstructive sleep apnea. (1995) (18)
Platelet monoamine oxidase. I: Effect of temperature, anticoagulant, and centrifugation technique. (1981) (18)
Correction: A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia (2009) (17)
Genetic association analysis of N‐methyl‐d‐aspartate receptor subunit gene GRIN2B and clinical response to clozapine (2016) (17)
Type I (brain type) creatine phosphokinase (CPK) activity in rat platelets (1972) (17)
The periodicities in and biometeorological relationships with bed occupancy of an acute psychiatric ward in Antwerp, Belgium (1993) (17)
Association study of BDNF and DRD3 genes in schizophrenia diagnosis using matched case–control and family based study designs (2010) (17)
Serum Enzyme Changes during Sleep Deprivation (1970) (17)
Motor endplate alterations in schizophrenic patients (1976) (17)
Lack of association of GPX1 and MnSOD genes with symptom severity and response to clozapine treatment in schizophrenia subjects (2009) (17)
Psychotic Continuum or Distinct Entities: Perspective from Psychopharmacology (1995) (17)
Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response (2010) (17)
Genetics and etiology of schizophrenia and bipolar disorder (2000) (17)
Rigidity, hyperpyrexia and coma following fluphenazine enanthate (2004) (17)
In vivo occupancy of dopamine receptors by antipsychotic drugs. (1992) (17)
GSK‐3β Interacts with Dopamine D1 Receptor to Regulate Receptor Function: Implication for Prefrontal Cortical D1 Receptor Dysfunction in Schizophrenia (2017) (17)
ACTH levels after the dexamethasone suppression test in depression. (1982) (16)
Serum-enzyme changes in newly admitted psychiatric patients. I. (1969) (16)
Seasonal variation and meteotropism in various self-rated psychological and physiological features of a normal couple (1992) (16)
Effect of 3-PPP, a putative dopamine autoreceptor agonist, on rat serum prolactin levels. (1981) (16)
Serum creatine phosphokinase and aldolase activity in acute schizophrenic patients and their relatives. (1970) (16)
The InterSePT suicide scale for prediction of imminent suicidal behaviors (2008) (16)
Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder (2001) (16)
Neurochemical changes during discontinuation of lithium prophylaxis. II. Alterations in platelet serotonin function. (1984) (16)
Oxidation sensitivity may be a useful tool for the detection of the hematotoxic potential of newly developed molecules: application to antipsychotic drugs. (1999) (16)
Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment? (2013) (16)
Platelet MAO activity and family history of schizophrenia (1982) (15)
Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain. (2014) (15)
Valproic acid treatment of clozapine-induced myoclonus. (1994) (15)
Clinical evidence for multiple dopamine receptors in man. (1979) (15)
Side effects of clozapine and their management. (1991) (15)
A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia (2003) (15)
Inhibitory effect of ritanserin on the 5-hydroxytryptophan-mediated cortisol, ACTH and prolactin secretion in humans (1991) (15)
Neurosteroid pregnenolone sulfate, alone, and as augmentation of lurasidone or tandospirone, rescues phencyclidine-induced deficits in cognitive function and social interaction (2018) (15)
Association study of GRIK1 gene polymorphisms in schizophrenia: case–control and family‐based studies (2012) (15)
Development of the Clozaril Patient Management System (2004) (15)
5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex. (2002) (15)
Serotonin-Dopamine Interactions and Atypical Antipsychotic Drugs (1993) (15)
The effect of ipsapirone and S(−)-pindolol on dopamine release in rat striatum and nucleus accumbens (1999) (15)
Schizoaffective disorder: is the news of its nonexistence premature? Editor's introduction. (1984) (15)
The Role of Dopamine D3 Receptor Partial Agonism in Cariprazine-Induced Neurotransmitter Efflux in Rat Hippocampus and Nucleus Accumbens (2019) (15)
Effects of chlorpromazine on serotonin uptake in blood platelets (1983) (15)
Enhanced serum cortisol response to 5-hydroxytryptophan in depression and mania. (1983) (15)
Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophrenia (2007) (15)
Paradoxical lithium neurotoxicity: a report of five cases and a hypothesis about risk for neurotoxicity. (1979) (15)
Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder (2011) (15)
Chlorpromazine-induced hypothermia and increased plasma creatine phosphokinase activity. (1971) (15)
Function of tuberoinfundibular dopamine neurons in pargyline- and reserpine-treated rats. (1984) (14)
Medical-claims databases in the design of a health-outcomes comparison of quetiapine ('Seroquel') and usual-care antipsychotic medication. (1998) (14)
Effect of Clozapine Treatment on Serotonin-2—Receptor Binding in the Blood Platelets of Schizophrenic Patients (1994) (14)
Pre-morbid asociality in neuroleptic-resistant and neuroleptic-responsive schizophrenia (1996) (14)
Neuroleptic withdrawal in schizophrenic patients. An idea whose time has come. (1995) (14)
Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians (2010) (14)
Adrenocorticotropic hormone, β-endorphin and cortisol responses to oCRH in Unipolar Depressed Patients Pretreated with Dexamethasone (1994) (14)
5HT2-receptor antagonists can attenuate submaximal haloperidol-induced catalepsy in rats (1995) (14)
The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia (2013) (14)
Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia (2020) (14)
Depolarizing GABAA current in the prefrontal cortex is linked with cognitive impairment in a mouse model relevant for schizophrenia (2021) (14)
Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain (2018) (14)
Effect of chronic phencyclidine or d-amphetamine treatment on [3H]spiroperidol binding in rat caudate-putamen and nucleus accumbens. (1982) (14)
Effect of metabolites of chlorpromazine on plasma prolactin levels in male rats. (1977) (14)
Effect of a novel benzamide, YM-09151-2, on rat serum prolactin levels. (1983) (13)
The Effect of Apomorphine, MK-212 (6-chloro-2-[1-piperazinyl]-pyrazine) and Placebo on Smooth Pursuit Gain and Corrective Saccades in Normal Subjects (1994) (13)
Investigation of the HSPG2 Gene in Tardive Dyskinesia – New Data and Meta-Analysis (2018) (13)
Serotonergic Function in the Affective Disorders: The Effect of Antidepressants and Lithium on the 5‐Hydroxytryptophan‐Induced Increase in Serum Cortisol a (1984) (13)
Lysergic acid diethylamide: Evidence for stimulation of pituitary dopamine receptors (1977) (13)
Selective desensitization of serotonin (5-HT) receptor-mediated hyperthermia by mianserin and other 5-HT antagonists (1987) (13)
Des-tyrosine-γ-endorphin: H-reflex response similar to neuroleptics (1981) (13)
Pituitary and adrenal hormone responsiveness to synachten in melancholic subjects versus subjects with minor depression (1993) (13)
Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine (2016) (13)
3H-imipramine binding in blood platelets of schizophrenic patients (1986) (13)
Isometric force control in schizophrenic patients with tardive dyskinesia (1991) (13)
In vitro effect of phencyclidine and other psychomotor stimulants on serotonin uptake in human platelets. (1980) (13)
Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia (2010) (13)
Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia (2004) (13)
Therapy-resistant schizophrenia (2010) (13)
Effect of intramuscular chlorpromazine on serum prolactin levels in schizophrenic patients and normal controls (1981) (13)
Serotonin receptors and antipsychotic drug action. (1993) (13)
Creatine phosphokinase activity and clinical symptomatology. A study in acute schizophrenic patients. (1973) (13)
Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes. (2015) (13)
No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain (2014) (12)
Genetic interactions in the adrenergic system genes: analysis of antipsychotic‐induced weight gain (2011) (12)
The influence of N-desmethylclozapine and clozapine on recognition memory and BDNF expression in hippocampus (2011) (12)
Brain and skeletal muscle monoamine oxidase activity in schizophrenia. (1980) (12)
Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: A meta-analysis of samples from three independent clinical trials (2018) (12)
α2-ADRENERGIC RECEPTORS: COMPARATIVE BIOCHEMISTRY OF NEURAL AND NON-NEURAL RECEPTORS, AND IN VITRO ANALYSIS IN PSYCHIATRIC PATIENTS (1982) (12)
Diagnostic concordance for schizophrenia as a function of sex. (1984) (12)
Correlation of plasma and CSF prolactin with CSF GABA during neuroleptic treatment. (1982) (12)
A longitudinal psychopathological schedule (1992) (12)
Association study of the gamma-aminobutyric acid type a receptor γ2 subunit gene with schizophrenia (2009) (12)
Relationships between lower plasma L-tryptophan levels and immune variables in depression (1993) (12)
Effect of buspirone on rat plasma prolactin levels and striatal dopamine turnover (2004) (12)
Genetic validation study of protein tyrosine phosphatase receptor type D (PTPRD) gene variants and risk for antipsychotic-induced weight gain (2018) (12)
Effects of amoxapine on serotonin uptake in human blood platelets of depressed patients and normal controls (1983) (12)
The effect of chronic clozapine on basal dopamine release and apomorphine-induced DA release in the striatum and nucleus accumbens as measured by in vivo brain microdialysis (1992) (12)
Lack of effect of tricyclic antidepressants on serum prolactin levels (1977) (12)
Treatment of delusional disorders with clozapine. (1994) (12)
The effect of mescaline, 3, 4-dimethoxyphenethylamine and 2, 5-dimethoxy-4-methylamphetamine on rat plasma prolactin: evidence for serotonergic mediation. (1978) (12)
Kinetic constants of platelet monoamine oxidase in schizophrenia. (1983) (12)
Selective reduction of striatal type II glucocorticoid receptors in rats by 3,4-methylenedioxymethamphetamine (MDMA). (1989) (12)
Effect of limb restraints on serum creatine phosphokinase activity in normal volunteers. (1977) (11)
Dexamethasone suppression test: technique and accuracy. (1982) (11)
Platelet MAO activity and the cortisol response to dexamethasone in major depression (1988) (11)
Discriminative stimulus properties of N-desmethylclozapine, the major active metabolite of the atypical antipsychotic clozapine, in C57BL/6 mice (2012) (11)
Presynaptic Receptors a Relevance to Psychotropic Drug Action in Man (1990) (11)
Biphasic effect of 5-methoxy-N,N-dimethyltryptamine on rat prolactin secretion (1983) (11)
Serum prolactin, psychopathology, and ventricular size in chronic schizophrenia (1984) (11)
Serum creatine phosphokinase (CPK) activity in monozygotic twins discordant for schizophrenia: heritability of serum CPK activity. (1976) (11)
Drugs and psychosocial treatment: editors' introduction. (1980) (11)
Serotonin accumulation by skeletal muscle (1977) (11)
The Effect of Lithium on Platelet Monoamine Oxidase Activity in Bipolar and Schizoaffective Disorders (1982) (11)
Atypical Antipsychotic Drugs: Clinical and Preclinical Studies (1996) (11)
Effect of Chlorpromazine treatment on Monoamine Oxidase activity in platelets isolated by the Corash method (1981) (11)
Effect of apomorphine plus 5-hydroxytryptophan on plasma prolactin levels in male rats. (1976) (11)
Acute administration of buspirone increases the escape of hypothalamic-pituitary-adrenal-axis hormones from suppression by dexamethasone in depression (1996) (11)
Neuromuscular abnormalities in the major mental illnesses. I. Serum enzyme studies. (1975) (11)
Release of creatine phosphokinase from muscle. I. Effect of polymyxin B, compound 48-80, and serotonin. (1971) (11)
Hormone response to 5-HTP (1983) (11)
Comparison of inpatients with major mental illness who do and do not consent to low-risk research (2003) (11)
R(+)-8-OH-DPAT, a selective 5-HT1A receptor agonist, attenuated amphetamine-induced dopamine synthesis in rat striatum, but not nucleus accumbens or medial prefrontal cortex (2000) (11)
Muscarinic receptor signaling contributes to atypical antipsychotic drug reversal of the phencyclidine-induced deficit in novel object recognition in rats (2017) (11)
Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans (2019) (10)
Multiple neurotransmitters involved in antipsychotic drug action (2003) (10)
Effects of phencyclidine and stress on plasma creatine phosphokinase (CPK) and aldolase activities in man (2004) (10)
Improvement in cognition following a switch to open-label ziprasidone from olanzapine, risperidone and conventional antipsychotics (2000) (10)
Protein kinase cAMP‐dependent regulatory type II beta (PRKAR2B) gene variants in antipsychotic‐induced weight gain (2014) (10)
Erratum: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT) (Archives of General Psychiatry (January 2003) 60 (82-91)) (2003) (10)
Characterization of rat skeletal muscle monoamine oxidase. (1977) (10)
Basic biology of clozapine: electrophysiological and neuroendocrinological studies (2004) (10)
Frontal cortex lesions modify the cataleptogenic properties of haloperidol but not of clozapine (1993) (10)
Clozapine in treatment of bromocriptine-induced psychosis. (1997) (10)
Contrasting Typical and Atypical Antipsychotic Drugs. (2021) (10)
Biogenic amines and serum prolactin levels during stress in male rats (1976) (10)
The significance of serotonin for neuropsychiatric disorders (1991) (10)
Effect of low-dose bromocriptine in treatment of psychosis: The dopamine autoreceptor-stimulation strategy (1983) (10)
SEROTONIN UPTAKE IN BLOOD PLATELETS AS A BIOLOGICAL MARKER FOR MAJOR DEPRESSIVE DISORDERS (1982) (10)
Introduction: Weight Gain: A Growing Problem in Schizophrenia Management (2001) (10)
Serotonin uptake in subpopulations of normal human blood platelets. (1982) (10)
Language-dependent performance on the letter fluency task in patients with schizophrenia (2014) (10)
A functional HTR1A polymorphism, rs6295, predicts short-term response to lurasidone: confirmation with meta-analysis of other antipsychotic drugs (2019) (10)
PCP: neurochemistry, treatment, and more. (1979) (10)
Effect of des-tyr-γ-endorphin in schizophrenia (1982) (10)
Catch-up saccade amplitude is related to square wave jerk rate. (1992) (10)
Labeling of creatine phosphokinase without loss of enzyme activity. (1975) (10)
Beyond serotonin. (1991) (10)
Plasma copper and dopamine-beta-hydroxylase in schizophrenia. (1982) (10)
Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics (2010) (10)
Suppression of the hypo- and hyperthermic responses to 5-HT agonists following the repeated administration of monoamine oxidase inhibitors (2004) (10)
Phencyclidine-induced inhibition of rat prolactin secretion: increased portal blood dopamine. (1985) (10)
Sulfotransferase 4A1 Haplotype 1 (SULT4A1-1) Is Associated With Decreased Hospitalization Events in Antipsychotic-Treated Patients With Schizophrenia. (2012) (10)
The Relationship between Wrist-Monitored Motor Activity and Serum CPK Activity in Psychiatric In-Patients (1979) (9)
Association of Serotonin2c Receptor Polymorphisms With Antipsychotic Drug Response in Schizophrenia (2019) (9)
Lower angiotensin I converting enzyme activity in melancholic subjects: A pilot study (1992) (9)
Effect of morphine, beta-endorphin and leu-enkephalin on 3H-spiroperidol binding to bovine pituitary membranes. (1979) (9)
Serum prolactin levels following intramuscular chlorpromazine: Two- and three-hour response as predictors of six-hour response (1979) (9)
Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia (2019) (9)
It Is Time to Take a Stand for Medical Research and Against Terrorism Targeting Medical Scientists (2008) (9)
LURASIDONE IN THE TREATMENT OF ACUTE SCHIZOPHRENIA: RESULTS OF THE DOUBLE-BLIND, PLACEBO-CONTROLLED PEARL 2 TRIAL (2010) (9)
Repeated administration of 5-methoxy-N,N-dimethyltryptamine to male rats potentiates stimulation of prolactin secretion by serotonin agonists. (1979) (9)
Effect of gamma-butyrolactone and baclofen on plasma prolactin in male rats. (1977) (9)
Multiple neuromuscular abnormalities in a paranoid schizophrenic (1980) (9)
Effect of neuroleptics on the schizophrenic syndrome. (1987) (9)
Association of FAS, a TNF-α receptor gene, with treatment resistant schizophrenia (2011) (9)
The effect of hypertension and obesity on the development of diabetes mellitus in patients treated with atypical antipsychotic drugs. (2004) (9)
Glucose-6-phosphate dehydrogenase deficiency in a psychiatric population: a preliminary study. (1982) (9)
Relationships between basal hypothalamic-pituitary-thyroid-axis activity and plasma haptoglobin levels in depression. (1994) (9)
Beyond Control of Acute Exacerbation: Enhancing Affective and Cognitive Outcomes (2003) (9)
Effect of subchronic treatment with imipramine, chlorpromazine and the combination on 3H-imipramine binding in rat blood platelets and frontal cortex. (1986) (9)
Finite mixture regression model analysis on antipsychotics induced weight gain: Investigation of the role of the serotonergic genes (2013) (9)
Plasma prolactin response to domperidone in acute schizophrenia and schizophreniform illness (1990) (8)
Neurochemistry of Schizophrenia (1999) (8)
The effects of clozapine on dopamine, 5-HT, and glutamate release in the rat medial prefrontal cortex (1991) (8)
Effect of 8-hydroxy-2-(di-n-propylamino) tetralin on rat prolactin secretion (1984) (8)
Indolethylamine-N-methyltransferase activity in psychiatric patients and controls. (1975) (8)
Serum prolactin levels in newly admitted psychiatric patients. (1974) (8)
Effect of pindolol on hormone secretion and body temperature: Partial agonist effects (2005) (8)
Biological Studies of DSM‐III Psychotic Disorders. I. Platelet Measures and Apomorphine‐induced Growth Hormone Response (1982) (8)
RMI-81,582, a novel antipsychotic drug (2004) (8)
Path analysis of the Zeus study provides evidence of a direct effect of ziprasidone on primary negative symptoms in chronic, stable, schizophrenia (2000) (8)
MDR1 gene in tardive dyskinesia scale scores: Comparison of strategies for quantitative trait haplotype analysis (2009) (8)
Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia (2010) (8)
The effects of atypical antipsychotic drugs on cognitive functioning in schizophrenia (1998) (8)
Regional selectivity in clozapine treatment? (2002) (8)
Prolactin and psychiatry. (1981) (8)
Hypercortisolism and depression. (1985) (8)
Risperidone and clozapine for treatment-resistant schizophrenia. (1999) (8)
Prolactin responses to domperidone in chronic schizophrenia (1992) (8)
Choreoathetosis induced by verapamil and lithium treatment. (1989) (8)
Predictors of Response to Clozapine (1996) (8)
Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action (2020) (7)
The effect of thiamine on monoamine oxidase. (1961) (7)
Association between the -2548G/A polymorphism of the leptin gene and antipsychotic-induced weight gain: Analysis of the CATIE sample and meta-analysis (2020) (7)
Antipsychotic and anticholinergic drugs (2012) (7)
Neuromuscular abnormalities in the major mental illnesses. II. Muscle fiber and subterminal motor nerve abnormalities. (1975) (7)
The American Psychiatric Press Textbook of Psychiatry (1988) (7)
Stimulation of rat prolactin secretion by indolealkylamine hallucinogens (1978) (7)
Effect of flupenthixol and butaclamol isomers on prolactin secretion in rats (1977) (7)
SERUM CREATINE PHOSPHOKINASE AND SERUM ALDOLASE LEVELS IN ACUTELY PSYCHOTIC PATIENTS (1974) (7)
Decreased serotonin2C receptor responses in male patients with schizophrenia (2015) (7)
Lack of association between HTR4 gene polymorphisms and schizophrenia in case–control and family-based samples (2010) (7)
A Mouse Model of Human Primitive Neuroectodermal Tumors Resulting from Microenvironmentally-Driven Malignant Transformation of Orthotopically Transplanted Radial Glial Cells (2015) (7)
Stimulatory Effects of L-5-Hydroxytryptophan on Postdexamethasone β-Endorphin Levels in Major Depression (1996) (7)
Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol (2020) (7)
Prolonged reversal of the phencyclidine-induced impairment in novel object recognition by a serotonin (5-HT)1A-dependent mechanism (2016) (7)
TPA-023 attenuates subchronic phencyclidine-induced declarative and reversal learning deficits via GABAA receptor agonist mechanism: possible therapeutic target for cognitive deficit in schizophrenia (2018) (7)
New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach (2019) (7)
New insights into schizophrenia through atypical antipsychotic drugs. (1988) (7)
Atypical antipsychotic drugs have their merits (2009) (7)
Investigation of melanocortin system gene variants in antipsychotic-induced weight gain (2014) (7)
Muscle cholinesterase: Effect of phencyclidine and ketamine on rat and human muscle cholinesterase activity (1980) (7)
Effect of subchronic lithium treatment on apomorphine-induced change in prolactin and growth hormone secretion. (1983) (7)
Neurochemical changes during discontinuation of lithium prophylaxis. I. Increases in clonidine-induced hypotension. (1984) (6)
Association study between the neurexin‐1 gene and tardive dyskinesia (2017) (6)
Prolactin and neuroleptics: clinical implications for efficacy and toxicity. The effect of neuroleptics and alpha-methyl-para-tyrosine on serum prolactin levels in laboratory animals and man. (1978) (6)
Cytotoxic effects of imipramine on platelets. (1974) (6)
3H-Imipramine binding in the blood platelets of normal twins (1990) (6)
The metabolites N-desmethylclozapine and N-desmethylolanzapine produce cross-tolerance to the discriminative stimulus of the atypical antipsychotic clozapine in C57BL/6 mice (2011) (6)
Differential effects of haloperidol, clozapine, and fluperlapine on tuberoinfundibular dopamine neurons and prolactin secretion in the rat (1987) (6)
Prolactin as a biomarker for treatment response and tardive dyskinesia in schizophrenia subjects: old thoughts revisited from a genetic perspective (2011) (6)
Importance of adjusting for correlated concomitant variables in psychiatric research (1988) (6)
Delayed activation of tuberoinfundibular dopamine neurons and suppression of prolactin secretion in the rat after morphine administration. (1986) (6)
Effect of (des-Tyr1)-γ-endorphin on Prolactin Secretion (1981) (6)
Effects of a series of substituted benzamides on rat prolactin secretion and 3H-spiperone binding to bovine anterior pituitary membranes. (1983) (6)
Occupancy of cortical and substantia nigra DA D2 receptors by typical and atypical antipsychotic drugs (2003) (6)
Neuroendocrine effects of psychotomimetic drugs (1981) (6)
Skeletal muscle morphology of depressed patients after medication. (1979) (6)
The 5-HT2C Receptor as a Target for Schizophrenia (2011) (6)
Effect of d- and l-amphetamine on rat plasma prolactin levels (1979) (6)
Treatment-resistant schizophrenia: the importance of early detection and treatment. Introduction. (1998) (6)
Effects of combined administration of imipramine and chlorpromazine on β- and α2-adrenergic receptors in rat cerebral cortex (1983) (6)
Association Study of Serotonin 3 Receptor Subunit Gene Variants in Antipsychotic-Induced Weight Gain (2017) (6)
The behavioral effects of nicotinamide adenine dinucleotide in chronic schizophrenia (2004) (6)
Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia (2018) (6)
Olanzapine: a new typical antipsychotic drug. (1996) (6)
Twenty-Four–Hour Measures of Heart Rate–Corrected QT Interval, Peak-to-End of the T-Wave, and Peak-to-End of the T-Wave/Corrected QT Interval Ratio During Antipsychotic Treatment (2019) (6)
Psychosis and genes with trinucleotide repeat polymorphism (1996) (6)
Neuroendocrine effects of typical and atypical antipsychotics in the rat (1987) (6)
Serotonin uptake in blood platelets of duchenne muscular dystrophy patients (1987) (6)
Is Clozapine Response Different in Neuroleptic Nonresponders vs Partial Responders?-Reply (1990) (6)
P.2.105 Efficacy and safety of aripiprazole versus perphenazine in treatment-resistant schizophrenia (2003) (6)
The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats (2012) (6)
Clozapine and suicide. (2002) (6)
Clozapine and Electroconvulsive Therapy-Reply (1990) (6)
Genetic studies in treatment-resistant schizophrenia (2010) (6)
Dopaminergic and serotonergic control of neuroendocrine function. (1984) (6)
Lack of association of NALCN genetic variants with schizophrenia (2011) (6)
Ketamine as an Anesthetic for Obtaining Plasma for Rat Prolactin Assays (1978) (5)
Clozapine treatment of persistent paroxysmal dyskinesia associated with concomitant paroxetine and sumatriptan use (1997) (5)
Distribution of type A and type B monoamine oxidase activities in rat and chicken skeletal muscle and nerves. (1979) (5)
Retention of sarcoplasmic calcium inhibits development of the phencyclidine-restraint experimental myopathy (1983) (5)
Atypical Antipsychotics: Clinical Advantages (1991) (5)
Neuroendocrinological Effects of MDMA in the Rat (1990) (5)
An autophagy-related protein Becn2 regulates cocaine reward behaviors in the dopaminergic system (2021) (5)
Correlation between MAO activity in blood platelets obtained by single and multiple centrifugations (1983) (5)
Effect of atypical and typical antipsychotic drugs on neuropsychological functions in early-stage schizophrenic patients (1992) (5)
Serum dopamine-beta-hydroxylase activity and lateral ventricular size in affective disorders and schizophrenia. (1984) (5)
Mg++-dependent adenosine triphosphatase activity in erythrocyte ghosts of schizophrenic patients. (1974) (5)
Platelet monoamine oxidase activity and schizophrenia. (1980) (5)
Relationship to the Dexamethasone Suppression Test (1985) (5)
Schizophrenia‐associated gene dysbindin‐1 and tardive dyskinesia (2020) (5)
Lithium and Serotonin Uptake by Platelets (1980) (5)
Melperone, an aytpical antipsychotic drug with clozapine‐like effect on plasma prolactin: contrast with typical neuroleptics (2009) (5)
Neuropsychology of Treatment-Resistant Schizophrenia (2010) (5)
Serotonin2A receptors in schizophrenia: relation to suicide. (1994) (5)
Hippocampal GABAA antagonism reverses the novel object recognition deficit in sub-chronic phencyclidine-treated rats (2018) (5)
Increased serum prolactin levels during phenothiazine and butyrophenone treatment of six postpartum women (1980) (5)
The alpha-7 nicotinic receptor partial agonist/5-HT3 antagonist RG3487 enhances cortical and hippocampal dopamine and acetylcholine release (2013) (5)
Role of the adrenal in an experimental myopathy (1977) (5)
Biological markers for depressive illness. (1982) (5)
Isoenzymes of monoamine oxidase in human skeletal muscle (1977) (5)
Development of a computerized adaptive diagnostic screening tool for psychosis (2021) (5)
Comparison of midday serum dopamine-beta-hydroxylase activity in depressed patients and normal controls. (1980) (4)
Do anticholinergic antagonize antipsychotic drug action? (1978) (4)
Serum creatine phosphokinase activity in psychiatrically hospitalized children. (1976) (4)
Clozapine and NMS (1993) (4)
Effect of neuroleptic drugs on platelet monoamine oxidase activity (1981) (4)
Prolactin stimulating effects of amoxapine and loxapine in psychiatric patients (1982) (4)
Biologic Studies of Suicide in Schizophrenia (1995) (4)
Dipeptidyl peptidase serum activity in depression, schizophrenia and mania: effects of antidepressive drugs, neuroleptics and valproate (1996) (4)
Effects of lithium carbonate on serotonin uptake in rat blood platelets (1983) (4)
Preliminary evidence that neuronal and glial density is increased and neuronal size is decreased in hippocampus in major depressive disorder (2002) (4)
Differential Effects of M 1 and 5-Hydroxytryptamine 1 A Receptors on Atypical Antipsychotic Drug-Induced Dopamine Efflux in the Medial Prefrontal Cortex (2009) (4)
Dopamine-2 and serotonin-2 receptor indices in clozapine treated schizophrenic patients (1993) (4)
The Role of Dopamine D 3 Receptor Partial Agonism in Cariprazine-Induced Neurotransmitter Efflux in Rat Hippocampus and Nucleus Accumbens (2019) (4)
A national plan for schizophrenia research: panel recommendations. Research resources. (1988) (4)
Beta adrenergic-mediated myofibrillar disruption and enzyme efflux in an experimental myopathy related to isometric muscle activity. (1979) (4)
In vitro and in vivo inhibition of rat liver, brain and muscle monoamine oxidase by chlorpromazine and imipramine. (1976) (4)
Hypothesis About Risk for Neurotoxicity (1979) (4)
CEREBROSPINAL FLUID (CSF) HOMOVANILLIC ACID (HVA), CYCLIC ADENOSINE MONO-PHOSPHATE (cAMP), PROLACTIN AND SERUM PROLACTIN IN ACUTE PSYCHOTIC PATIENTS AT TWO POINTS DURING EARLY CHLORPROMAZINE (CPZ) TREATMENT (1979) (4)
Estimating transitions between symptom severity states over time in schizophrenia: a Bayesian meta‐analytic approach (2006) (4)
The Breast Metaphor and the Group (1968) (4)
Substance Abuse in Schizophrenia: Biological Factors Mediating Comorbidity and the Potential Role of Atypical Antipsychotic Drugs (2001) (4)
Distribution and pharmacology of the enkephalins (1979) (4)
Reserpine-induced DST nonsuppression in rats (1990) (4)
P.3.c.046 Long-term safety and maintenance of effect of asenapine in patients with acute exacerbation of schizophrenia (2009) (4)
EFFECT OF KETAMINE ON CREATINE PHOSPHOKINASE LEVELS (1975) (4)
Neuroleptic-induced reductions in serum dopamine-beta-hydroxylase in schizophrenia. (1983) (4)
Duration of Untreated Psychosis and Premorbid Functioning: Relationship with Treatment Response and Treatment-Resistant Schizophrenia (2010) (4)
Glucocorticoid receptor function in depression (1987) (4)
S.25.03 Reducing risk of suicide in schizophrenia (2003) (4)
Activity of tuberoinfundibular dopaminergic neurons and concentrations of serum prolactin in the rat following lithium administration (2004) (4)
Actions of typical and atypical antipsychotics on tuberoinfundibular dopamine neurons. (1989) (4)
PHOSPHODIESTERASE 4B GENETIC VARIANTS ARE NOT ASSOCIATED WITH ANTIPSYCHOTIC-INDUCED TARDIVE DYSKINESIA (2010) (4)
Introduction. Multiple roles and actions of serotonin systems (1991) (4)
The role of isometric muscle tension in the production of muscle toxicity by phencyclidine and restraint stress (1975) (4)
Olanzapine causes greater increases in serum lipids than risperidone (2003) (4)
Effects of chlorpromazine on plasma prolactin and chlorpromazine levels [proceedings]. (1977) (4)
Biological Studies of the Nosology of the Major Psychoses: A Status Report on the Schizoaffective Disorders (1986) (4)
Multireceptor atypical antipsychotic drugs (2000) (4)
The effect of muscimol on prolactin secretion in male rats. (1978) (3)
Hoffmann reflex abnormalities in psychotic patients. (1979) (3)
Tying comparative effectiveness information to decision-making and the future of comparative effectiveness research designs: the case for antipsychotic drugs. (2012) (3)
The cimetidine-induced increase in prolactin secretion in schizophrenia: effect of clozapine (2005) (3)
Increased S(−)-Apomorphine–Induced Vacuous Chewing and Attenuated Effect of Chronic Haloperidol Treatment in Streptozotocin-Induced Diabetic Rat (1997) (3)
Neuropharmacological studies of prolactin secretion. (1978) (3)
Muscle toxicity produced by phencyclidine and restraint stress. (1972) (3)
Clozapine: neuroendocrine studies of an atypical neuroleptic. (1986) (3)
Motor mechanisms in schizophrenic patients with tardive dyskinesia (1994) (3)
Effect of MK-212, a centrally acting serotonin agonist, on prolactin, cortisol and body temperature in schizophrenia (1995) (3)
Atypical Antipsychotic Drugs: Mechanism of Action (2007) (3)
Common Variants near the Melanocortin 4 Receptor Gene are Associated with Severe Antipsychotic Drug-induced Weight Gain (2014) (3)
Effect of decapitation on blood levels of creatine phosphokinase. (1971) (3)
The Novel Antipsychotic Drug Lurasidone Enhances NMDA Receptor-Mediated Synaptic Responses (2011) (3)
Prolactin and breast cancer. (1978) (3)
New insights into schizophrenia through atypical anti-psychotic drugs. Comments on ???The Current Status of the Dopamine Hypothesis of Schizophrenia??? (Neuropsycho-pharmacology 1988;1:179???86) (1990) (3)
Corrigendum to “Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia” [Schizophr. Res. 57 (2002) 127–138] (2003) (3)
Effects of MK-212 on regional cerebral blood flow in humans (1993) (3)
Lesions of the myofibril in myopathic and normal tissue from seven striated muscles (1979) (3)
Co-therapy with pimavanserin and risperidone 2 mg provides an improved clinical profile (2008) (3)
Introduction: Side Effects of Antipsychotic Medications: Physician's Choice of Medication and Patient Compliance (2000) (3)
Effect of 6-methoxy-tetrahydro-beta-carboline on serum prolactin levels of male rats. (1978) (3)
Visual feedback in force control of schizophrenics (1993) (3)
A within‐subject consideration of the psychotic spectrum disorder concept in a patient in remission associated with cortical gray matter recovery (2018) (3)
Current practices and future developments in the pharmacotherapy of mental disorders : proceedings of the International Conference on Current Practices and Future Developments in the Pharmacotherapy of Mental Disorders, Venice, 10-12 October 1990 (1991) (3)
The effect of high vs. low dose lurasidone on eye movement biomarkers of prefrontal abilities in treatment-resistant schizophrenia (2019) (3)
Effect of 5-hydroxytryptophan on H-reflex recovery curves in normal subjects and patients with affective disorders (1988) (3)
Dr. Meltzer Replies (1979) (3)
The role of serotonin in the mechanism of action of antipsychotic drugs: Does 5-HT also have a role in the etiology of schizophrenia? (1989) (3)
Platelet serotonin studies in affective disorders: Evidence for a serotonergic abnormality? (2012) (3)
Response: Negative Symptoms Redux (2000) (3)
Correction and amplification: cortisol response to 5-HTP. (1986) (3)
Effect of indole hallucinogens, mescaline and DMPEA on rat plasma prolactin (1977) (3)
Effect of two dopamine agonists, TL-99 and 3-PPP, on prolactin secretion in the rat. (1983) (3)
The alpha-7 receptor agonist EVP-6124 increases dopamine and glutamate efflux in rat medial prefrontal cortex and nucleus accumbens (2011) (3)
Buspirone does not produce a 5-HT1A-mediated decrease in temperature in man (1991) (3)
Effect of piperoxane on rat plasma prolactin. (1978) (3)
Effect of chlorpromazine on H-reflex recovery curves in normal subjects and schizophrenic patients (1982) (3)
Indole): a Novel 5-ht 2c Receptor Selective Agonist with Preclinical Antipsychotic-like Activity (2006) (2)
Melperone, an atypical antipsychotic drug, in the treatment of schizophrenia: dose-response analysis on effectiveness and tolerability, and efficacy for treatment-resistant schizophrenia and cognitive function (2004) (2)
The effect of GABA and muscimol on plasma prolactin in male rats (1978) (2)
Pimavanserin augments the efficacy of atypical antipsychotic drugs in a mouse model of treatment-refractory negative symptoms of schizophrenia (2021) (2)
Liver enzyme CYP2D6 gene and tardive dyskinesia. (2020) (2)
The effect of adjunctive armoda fi nil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia / schizoaffective disorder : A randomized , double-blind , placebo-controlled trial ☆ (2011) (2)
Proceedings: Serum prolactin levels in newly admitted psychiatric patients. (1974) (2)
Differential effect of clozapine on psychopathology and cognitive dysfunction in treatment-resistant schizophrenics (1991) (2)
RELATIVE POTENCIES OF DOPAMINE AGONISTS ON PROLACTIN SECRETION IN RATS (1979) (2)
The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens (2014) (2)
Search for unstable DNA in schizophrenia (1998) (2)
Neuromuscular dysfunction and vulnerability to psychosis. (1979) (2)
A Naturalistic Follow-up Study (2017) (2)
Ultrasensitive assay for measuring the intact (1-39) ACTH molecule: an asset in depression research. (1994) (2)
Perlapine: Relationship between stimulation of prolactin secretion and antipsychotic activity (1977) (2)
Relationships between in vivo cellular immunity and haptoglobin plasma levels in major depression (1993) (2)
Role of the Serotonergic System in Pituitary Hormone Secretion: The Pharmacologic Challenge Paradigm in Man (1993) (2)
Schizophrenia and Suicide: Treatment Optimization (2014) (2)
Creatine Phosphokinase and Psychiatric Illness (1974) (2)
Effect of typical and atypical antipsychotic drugs on the in vivo binding of [3H]N-methyl-spiperone to serotonin-2 and dopamine-2 receptors in rat brain (1991) (2)
Novel histamine H1 gene polymorphism and clozapine-induced weight gain (2000) (2)
Cognitive function in stable outpatients switched to ziprasidone (2002) (2)
P.3.c.018 Genetic predictors of cognitive function and response to treatment in schizophrenia (2006) (2)
Serum creatine phosphokinase activity in newly admitted psychiatric patients. II. (1971) (2)
Effect of benzamide drugs on prolactin secretion: relation to the dopamine receptor. (1982) (2)
PHENCYCLIDINE INHIBITS THE ACTIVITY OF STRIATAL TYROSINE HYDROXYLASE IN VIVO (1979) (2)
Prefrontal sulcal prominence is inversely related to treatment response to clozapine in schizophrenia (1991) (2)
Plasma CPK levels in monozygotic and dizygotic twins discordant for schizophrenia. (1979) (2)
The effect of adrenalectomy on MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis and depletion of serotonin (1992) (2)
Plasma creatine phosphokinase activity in the rat after tenotomy or denervation. (1973) (2)
Why do cortical long-axoned cells and putative interneurons behave differently during the sleep-waking cycle? (1978) (2)
Introduction: Cardiovascular and Metabolic Risks Associated With Schizophrenia and Antipsychotic Drug Treatment (2002) (2)
Testing Multiple Novel Mechanisms for Treating Schizophrenia in a Single Trial (2006) (1)
Phencyclidine (PCP)–Induced Deficits in Novel Object Recognition (2016) (1)
Pharmacogenetics in the Treatment of Schizophrenia (2014) (1)
Clozapine's effect on primary negative symptoms and the initial level of symptom severity as a predictor of response (2001) (1)
Refractory Psychosis: Treatment Options and Strategies (2014) (1)
The effect of pyridine aldoxime dodecyliodide on monamine oxidase and bound amines. (1962) (1)
Effect of blood serum or plasma from schizophrenic patients and others on an action of 3,4-dimethoxyphenylethylamine: a failure to replicate. (1969) (1)
Cognitive Function and Functional Outcome in Schizophrenia (2009) (1)
Release of creatine phosphokinase from muscle. II. Effect of multiple doses of polymyxin B or compound 48-80 on increases in plasma enzyme levels. (1973) (1)
Mental health care from the public perspective : The Texas Medication Algorithm Project. Discussion (1999) (1)
Serotonin and negative symptoms (1995) (1)
SKELETAL MUSCLE MONOAMINE OXIDASE ACTIVITY IN PSYCHIATRIC PATIENTS AND NORMAL CONTROLS (1979) (1)
Poster #T48 INVESTIGATION OF THE PRO-MELANIN-CONCENTRATING HORMONE GENE IN ANTIPSYCHOTIC INDUCED WEIGHT GAIN (2014) (1)
Ziprasidone’s long-term efficacy and tolerability in schizophrenia (2002) (1)
Repeated administration of drugs known to inhibit the activity of serotonergic neurons potentiates the prolactin-releasing effect of serotonin agonists (1981) (1)
STIMULATION ADRENAL AND PITUITARY HORMONE SECRETION BY SEROTONERGIC AGENTS IN THE AFFECTIVE DISORDERS (1984) (1)
A Farewell to Editorship (1998) (1)
Chlorgyline (CHL) potentiates inhibitory effects of dopamine (DA) on rat plasma prolactin (PRL) (1979) (1)
Essays in Neurochemistry and Neuropharmacology, Vol. 1 (1978) (1)
The Rise of Psychopharmacology and the Story of CINP (2000) (1)
Adenosine 3',5'-monophosphate and mania. (1971) (1)
The concept of schizophrenia and the phenomenological models of kraepelin, bleuler and schneider: A confirmatory factor analysis (1995) (1)
Serotonin uptake in blood platelets of psychiatric patients (1982) (1)
Improvement in cognitive functions and psychopathology in treatment-refactory schizophrenic patients receiving clozapine (1993) (1)
Haptoglobin polymorphism may be associated with unipolar major depression. Am J In (1994) (1)
Antipsychotic drugs: A new era (2000) (1)
NMDAR and D1 receptor genes in the response to clozapine treatment and negative symptoms (2005) (1)
Side Effects of Antipsychotic Medications: Physician's Choice of Medication and Patient Compliance. Dallas, Texas, California. January 22, 1999. Proceedings of a roundtable. (2000) (1)
Comparative Effectiveness Research For Antipsychotic Medications : HowMuch Is Enough ? (2009) (1)
Serotonergic mechanisms in schizophrenia: Evolution and current concepts (2006) (1)
Des-tyrosine-gamma-endorphin: H-reflex response similar to neuroleptics. (1981) (1)
Creatine phospholinase activity in cerebrospinal fluid. (1971) (1)
A novel role for GAPDH-MAO B cascade in ethanol-induced cellular damage (2010) (1)
444. Effect of apomorphine on plasma cortisol in schizophrenia (1998) (1)
Prolactin secretion: An update (1981) (1)
Serum Creatine Kinase in Acute Psychosis (1975) (1)
DNA methylation at 5-HT1A receptor promoter C(−1019)G polymorphism CpG sites in schizophrenia and depression (2008) (1)
Daytime variation in serum prolactin level in patients receiving oral and depot antipsychotic medication. (1981) (1)
Attention and motion perception (1994) (1)
Aromatic Amino Acid Hydroxylases and Mental Disease (1983) (1)
Creatine kinase levels during treatment with atypical antipsychotic agents (2002) (1)
Studies of Ventricular Enlargement-Reply (1996) (1)
Creatine Phosphokinase Activity in Psychiatric Patients (1973) (1)
SYMPOSIUM ATYPICAL ANTIPSYCHOTICS : CLINICAL ADVANTAGES (1991) (1)
O-27-7 Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia (1996) (1)
Schizophrenia Treatment Strategies (1996) (1)
The Prozac pipeline (2004) (1)
Morphological effects of Compound 48-80, polymyxin B sulfate, and dextran on rat skeletal muscle. (1973) (1)
Schizophrenia risk loci from xMHC region were associated with antipsychotic response in chronic schizophrenic patients with persistent positive symptom (2022) (1)
Biochemical, immune and metabolic correlates of seasonal variation in violent suicide in Belgium (1996) (1)
Progress in Neurotherapeutics and Neuropsychopharmacology: Testing multiple novel mechanisms for treating schizophrenia in a single trial (2006) (1)
Antipsychotic adverse reactions in schizophrenia: A pharmacogenetic study of weight gain and tardive dyskinesia. (2000) (1)
28 EFFECTS OF FLUOXETINE ON SERUM mCPP CONCENTRATION IN DEPRESSED PATIENTS (1995) (1)
Clinical Pharmacology in Psychiatry (1993) (1)
Schizophenia in a Molecular Age: Review of Psychiatry, vol. 18 (2000) (1)
Lack of effect of ouabain on creatine phosphokinase efflux from skeletal muscle. (1975) (1)
Plasma levels and dosing strategies in schizophrenic patients receiving clozapine (1995) (1)
Mechanism of action of clozapine — like atypical antipsychotic drugs (1991) (1)
Plasma Clozapine and Desmethylclozapi (1994) (1)
Interpretation of CPK Activity (1974) (1)
Long-term efficacy of ziprasidone in schizophrenia (2001) (1)
Atypical antipsychotic drugs and organization of long-term semantic memory: multidimensional scaling analysis of category fluency performance in schizophrenia (2006) (1)
Discovery of Highly Potent Serotonin 5-HT2 Receptor Agonists Inspired by Heteroyohimbine Natural Products. (2022) (1)
Effect of subchronic treatment with neuroleptic, imipramine, and the combination on serotonin receptor binding in rat cerebral cortex. (1984) (1)
Role of advanced glycation end products in the longitudinal association between muscular strength and psychotic symptoms among adolescents (2022) (1)
Functional magnetic resonance imaging of the motor cortex in schizophrenia: Procedures and initial observations (1995) (1)
S.18.03 An evidence-based approach to reducing the risk of suicide in schizophrenia (2004) (1)
The effect of buspirone, a serotonin1A agonist, on cognitive function in schizophrenia (2003) (1)
THE RELATIONSHIP BETWEEN DOPAMINE D2 RECEPTOR OCCUPANCY BY ATYPICAL ANTIPSYCHOTIC DRUGS AND COGNITIVE FUNCTION IN PATIENTS WITH SCHIZOPHRENIA (2008) (1)
Immunological Disturbances in Psychiatric Patients-Reply (1986) (1)
Repeated administration of rapastinel produces exceptionally prolonged rescue of memory deficits in phencyclidine-treated mice (2022) (1)
Enzymic, electrophoretic and immunoreactive properties of labeled MM and BB isoenzymes of human creatine kinase. (1978) (1)
Dexamethasone and prolactin in depression. (1982) (1)
227. Validation Study in Two Genome-Wide Significant Risk Variants for Antipsychotic-Induced Weight Gain (2017) (1)
Healy Redux : In response to Healy (2003) (1)
Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week placebo-controlled studies (PAL-SCH-303/304/305) (2007) (0)
Action of atypical antipsychotics. Authors' reply (2002) (0)
Novel Treatments Derived from Understanding Atypical Antipsychotic Drug Efficacy for Positive and Negative Symptoms and Cognitive Impairment in Schizophrenia and Preclinical Models (2019) (0)
Chronic clozapine, but not typical antipsychotic agents, increase lymphocyte glucocorticoid receptors in schizophrenics (1991) (0)
Effects on serotonin and dopamine receptors in the mechanism of atypical antipsychotic drugs (2002) (0)
BRIEF REPORTS Clozapine-Induced Myoclonus Seizures and Generalized (1996) (0)
P.3.15 Serum creatine kinase levels and neuromuscular dysfunction in psychiatric patients: new results of follow-up study (2009) (0)
Pharmacogenetics of antipsychotic induced weight gain and tardive dyskinesia (2000) (0)
Marketing Drugs to Mend Minds (2002) (0)
Screening the ‘receptorome’ to discover novel proximal molecular targets of atypical antipsychotic drug actions (2003) (0)
Tolerance to the acute biochemical effects of neuroleptics: CSF homovanillic acid and serum prolactin (1981) (0)
Serotonin Agonist Induced Corticosterone and Prolactin Secretion: Role of 5-HT2 and 5-HT1A Receptors (1990) (0)
Influences of age and gender on cerebral morphology on computed tomography in schizophrenia (1993) (0)
A new understanding : neurological basis and long-term outcome of schizophrenia : CINP Congress, Washington, D.C., June 28, 1994 (1996) (0)
P.1.a.002 Glial cell-derived neurotrophic family (GFR) alpha 1 receptor polymorphisms and weight change during clozapine treatment (2008) (0)
Worldview of Psychiatry (2004) (0)
P.3.c.065 Comparison of multifactor dimensionality reduction (MDR) and neural network analysis: serotonergic system genes and antipsychotic response (2010) (0)
Awareness of illness moderates self-assessment of psychotic symptoms (2021) (0)
Better Than Prozac: Creating the Next Generation of Psychiatric Drugs by Samuel H Barondes (2004) (0)
Title Page Running Title Page Runing Title: 5ht2ar Antagonism and Reversal of Pcp Deficits in nor Corresponding Author (0)
Publishing & Business Staff (2015) (0)
Platelet MAO and family history of schizophrenia: Method and madness (1983) (0)
PM430. Blonanserin reversed phencyclidine-induced novel object recognition deficit and induced cortical dopamine and acetylcholine efflux through dopamine D3 receptor antagonism (2016) (0)
Neuroleptic-Nonresponsive Schizophrenic Patient (1992) (0)
LONGITUDINAL PROSPECTIVE EVALUATION OF SERUM CREATINE KINASE LEVELS AND NEUROMUSCULAR DYSFUNCTION IN SCHIZOPHRENIA PATIENTS: NEW RESULTS OF FOLLOW-UP STUDY (2008) (0)
ラット内側前頭前野及び側坐核におけるアンフェタミン誘発性ドーパミン遊離に対するセロトニン2A受容体作動薬の効果(Serotonin 2A receptor stimulation by DOl, a serotonin 2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.) (2003) (0)
Psychotropic Drugs in Psychiatry (1982) (0)
Isoenzymes of creatine phosphokinase in white blood cells (1977) (0)
Male to Female Schizophrenic Patients (1984) (0)
5-HT1A parital agonism and 5-HT7 antagonism restore episodic memory in subchronic phencyclidine-treated mice: role of brain glutamate, dopamine, acetylcholine and GABA (2018) (0)
Long-Term Outcome of Clozapine in Treatment-Resistant Schizophrenia (2023) (0)
GENETIC ASSOCIATION ANALYSIS OF THE GFR ALPHA GENES WITH SCHIZOPHRENIA AND CLOZAPINE RESPONSE (2008) (0)
88-8 Sex differences in plasma homovanillic acid levels in schzophrenia and normal controls: Relation to neuroleptic resistance (1997) (0)
Effects of corticotrophin-releasing factor receptor 1 antagonists on amyloid-β and behavior in Tg2576 mice (2014) (0)
Cost-utility analysis in schizophrenia. Discussion (1999) (0)
Pharmacogenetic dissection of central and peripheral candidate genes in atypical antipsychotic-induced weight-gain (2001) (0)
Effect of theophylline on alkaline phosphatase activity of denervated skeletal muscle fibers. (1973) (0)
Altered Fiber Radial Diffusivity in Schizophrenia Revealed by HARDI (2010) (0)
C.08.02 The multifunctional receptor profile of asenapine: clinical implications (2012) (0)
of Phenomenology and Demographic Characteristics (1988) (0)
P.2.082 Neuromuscular dysfunction in neuroleptics-treatedpsychiatric patients (2004) (0)
Letter: Effect of ketamine on creatine phosphokinase levels. (1975) (0)
Serotonin mechanisms in schizophrenia (1994) (0)
Platelet Monoamine Oxidase and Plasma Amine Oxidase in Psychiatric (2005) (0)
59 POLYGENIC RISK SCORES ANALYSES IN ANTIPSYCHOTIC-INDUCED WEIGHT GAIN (2019) (0)
Scopolamine reduces clozapine-induced dopamine release in rat striatum (2001) (0)
Studies on the biology of the neuroactive amines; a morphologic and pharmacologic approach (1963) (0)
on The metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there diﬀerences? (2005) (0)
Medical-claims databases in the design of a health-outcomes comparison of quetiapine (`Seroquel' 1 Seroquel is a trademark, the property of Zeneca Limited. 1 ) and usual-care antipsychotic medication (1998) (0)
Plasma creatine phosphokinase levels in rats following lysergic acid diethylamide (1975) (0)
adherence, a decline in the mortality rate and a fall in the danger of medication mistakes. There was also the possibility of an improvement in cognitive function and quality of life. Switching from antipsychotic polyphar- (2006) (0)
Clinical Aspects of Schizophrenia (1999) (0)
S.01.05 The molecular basis for add-on therapy for psychopathology, cognition and mood in schizophrenia (2006) (0)
Drs. Meltzer and Jayathilake reply (2008) (0)
Outcome in schizophrenia : Beyond symptom reduction. Discussion (1999) (0)
INTRODUCTION (1998) (0)
Neurotensin receptor agonists and antagonists for schizophrenia [13] (multiple letters) (2005) (0)
T38 Preliminary Model For The Genetic Prediction Of Clozapine Response (2017) (0)
Creatine phosphokinase activity in blacks vs whites. (1978) (0)
117. Differential effects of typical and atypical antipsychotics on 5-HT release (1996) (0)
Symposium - Atypical antipsychotics: Clinical advantages: Introduction (1991) (0)
Contents Vol. 2, 2016 (2017) (0)
Creatine phosphokinase activity in blacks. (1976) (0)
F1. GENOME-WIDE ASSOCIATION STUDIES SUGGESTED ASSOCIATION BETWEEN DGKB AND ANTIPSYCHOTIC INDUCED WEIGHT GAIN IN EUROPEANS AND AFRICAN AMERICANS (2018) (0)
Effect of clozapine on negative symptoms (1995) (0)
SA1 REPLICATION OF RS300774, A GENETIC BIOMARKER NEAR ACP1, ASSOCIATED WITH SUICIDE ATTEMPTS IN PATIENTS WITH SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER: RELATION TO BRAIN CHOLESTEROL BIOSYNTHESIS (2019) (0)
Alpha-1A adrenergic (ADRA1A) and serotonin 6 (HTR6) receptor gene polymorphisms and clinical response to clozapine (2001) (0)
Genomics, Transcriptomics and Methylomics: Alternative Approaches for the Analysis of Serotonin System and Antipsychotic Response (2009) (0)
Serum Creatine Phosphokinase Activity in Acute Psychosis (1973) (0)
Subject Index Vol. 49, 1989 (1989) (0)
Activation of dopamine receptor 2 (DRD2) prompts transcriptomic and metabolic plasticity in glioblastoma (2018) (0)
313 Relationship between plasma cortisol and cognitive function in schizophrenia (1997) (0)
149 Large or expanded CAG/CTG trinucleotide repeats as an etiological factor in schizophrenia (1997) (0)
Neuropharmacology of Serotonin (1987) (0)
Relative activity of cerebral subcortical gray matter in varying states of attention and awareness in normal subjects and patient studies (1985) (0)
Unmet Needs in Patients with Schizophrenia (2020) (0)
History of substance abuse and response to clozapine treatment (1993) (0)
93 Phosphoinositide signaling activity in postmortem brain from subjects with schizophrenia or alcohol dependence (1997) (0)
Subject Index Vol. 29, 1994 (1994) (0)
Dexamethasone Suppression Test: Technique and Accuracy-Reply (1982) (0)
107-3 Impact of pscyhoimmunology in research at major psychoses (1997) (0)
Our Goals, Our Challenges (1994) (0)
Outcome in schizophrenia : Beyond symptom reduction. Discussion (1999) (0)
Letter: Interpretation of CPK activity. (1974) (0)
S.09.02 Serotonin-related strategies for the treatment of schizophrenia (1996) (0)
A Concise Guide to Understanding Suicide: Clozapine (2014) (0)
The role of the medial prefrontal cortex in the expression of atypical preclinical behavioural effects of clozapine (1993) (0)
Pharmacologic studies of the Hoffmann reflex recovery curve in humans (1981) (0)
Serotonin (5-HT)1A receptor agonism and 5-HT7 receptor antagonism ameliorate the subchronic phencyclidine-induced deficit in executive functioning in mice (2015) (0)
T7. PHARMACOGENETIC OF TARDIVE DYSKINESIA -- A FOLLOW-UP ON THE VALBENAZINE TARGET VMAT2/SLC18A2 (2018) (0)
Letter to the editors (0)
Abstract 53. Immunoglobulin Studies in psychiatric disease patients (1985) (0)
Monitoring clozapine. (1990) (0)
Effects of acute and chronic dexamethasone treatment on stimulated prolactin secretion in the rat. (1987) (0)
Skeletal muscle abnormalities in psychiatric patients and their first-degree relatives (1974) (0)
239 – White matter abnormalities in schizophrenia detected by diffusion tensor imaging (2008) (0)
Untitled Page (2012) (0)
Dr. Meltzer and Ms. Tueting Reply (1983) (0)
Pharmacoeconomic factors related to the treatment of schizophrenia. Concluding discussion. (1999) (0)
The neurochemical basis of psychiatric disorders (2020) (0)
SU87 GENETIC PREDICTORS OF ANTIPSYCHOTIC RESPONSE TO LURASIDONE IDENTIFIED IN A GENOME-WIDE ASSOCIATION STUDY AND BY SCHIZOPHRENIA RISK GENES (2019) (0)
P.3.07 Antipsychotic agents and neuromusculardysfunction (2005) (0)
Atypical antipsychotic drugs: The 5-HT2/DA2 ratio (2012) (0)
Perospirone: A Viewpoint by Herbert Y. Meltzer (2001) (0)
PM493. Interactions of tardive dyskinesia with cognitive function in patients with schizophrenia: worsening of working memory with clozapine treatment (2016) (0)
Race and platelet MAO activity in schizophrenic patients (1988) (0)
Enough ? Comparative Effectiveness Research For Antipsychotic Medications : How Much Is (2009) (0)
Receptors and Ligands in Psychiatry AMAR K. SEN and TYRONE LEE, 578 pp., ill., Cambridge, UK, Cambridge University Press, 1988. $130.00 (1990) (0)
Sertindole: A viewpoint (1996) (0)
Relationship between quality of life and symptomatology in schizophrenia (1998) (0)
RELATIONSHIP BETWEEN POSITIVE AND NEGATIVE SYMPTOMS: RESPONSE TO ANTIPSYCHOTIC DRUGS AND STRUCTURAL BRAIN ABNORMALITIES (1994) (0)
Magnetic Resonance Imaging of Schizophrenia and Alzheimer’s Disease (2010) (0)
Clozapine prolongs hypotonic immobility in rats with bilateral 6-hydroxydopamine lesions of the striatum (2004) (0)
Front & Back Matter (2012) (0)
Isoenzymes of manoamine oxidase in human skeletal muscle. (1977) (0)
Comparing responses to ‘typical’ and ‘atypical’ antipsychotic drugs in schizophrenia: A multidimensional perspective (1999) (0)
Origins of Psychopharmacology from CPZ to LSD (1971) (0)
Dr. Lowy and Associates Reply (1985) (0)
A81 THEDISCRIMINATIVESTIMULUSPROPERTIESOF THE ATYPICAL ANTIPSYCHOTICCLOZAPINE INC57BL/6 MICE (2005) (0)
Erratum: SR46349-B, a 5-HT2A/2C Receptor Antagonist, Potentiates Haloperidol-induced Dopamine Release in Rat Medial Prefrontal Cortex and Nucleus Accumbens⋆ (2002) (0)
A functional HTR1A polymorphism, rs6295, predicts short-term response to lurasidone: confirmation with meta-analysis of other antipsychotic drugs (2019) (0)
PM389. Preliminary Genetic Model Predicting Clozapine Response (2016) (0)
Platelet MAO in functional psychoses with evidence of brain atrophy. (1985) (0)
Serotonin Uptake in Blood Platelets of Acute Schizophrenics-Reply (1983) (0)
A survey to examine psychiatrists?? attitudes and patterns of antipsychotic prescribing practices for schizophrenia in the USA and Japan (2006) (0)
Genetic and obstetrical determinants of cerebral morphology on computed tomography in schizophrenia (1993) (0)
Measurement of hippocampal glucocorticoid receptors in suicide (1995) (0)
Atypical antipsychotics: how do they work? (1993) (0)
Ziprasidone : a viewpoint by herbert y. Meltzer. (1997) (0)
A Randomized, Double-Blind Comparison of Clozapine and High-Dose Olanzapine in Treatment-Resistant Patients With Schizophrenia. Commentary (2008) (0)
Oakley Ray, 1931–2007 (2008) (0)
High-Dose Olanzapine Versus Clozapine. Authors' reply (2008) (0)
Effects of combined administration of imipramine and chlorpromazine on beta- and alpha 2-adrenergic receptors in rat cerebral cortex. (1983) (0)
Clinical Services Research Panel (1992) (0)
Polygenic risk scores analyses of psychiatric and metabolic traits with antipsychotic-induced weight gain in schizophrenia: an exploratory study. (2023) (0)
Neuropharmacology and Analgesia 5-HT 2 A and 5-HT 2 C receptor stimulation are differentially involved in the cortical dopamine ef fl ux — Studied in 5-HT 2 A and 5-HT 2 C genetic mutant mice (2010) (0)
Submission Category: Regular Research Article Catechol-O-methyltransferase Val158Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizo-affective disorder patients: a meta-analysis. (2016) (0)
M172. POLYGENIC RISK SCORES ANALYSES IN ANTIPSYCHOTIC-INDUCED WEIGHT GAIN (2020) (0)
Drs. Meltzer and Arvanitis Reply (2005) (0)
Binding of atypical antipsychotic drugs to novel neurotransmitter receptors (1996) (0)
Human platelet monoamine oxidase activity and in vivo manipulation of plasma glucose concentration. (1980) (0)
GLIAL CELL LINE–DERIVED NEUROTROPHIC FACTOR RECEPTOR ALPHA 2 IS ASSOCIATED WITH TARDIVE DYSKINESIA (2010) (0)
P.2.001 The effects of antipsychotic agents on sceletal muscle of psychiatric patients as it evidences by their serum creatine kinase activity (2003) (0)
Denervation and reinnervation of skeletal muscle in psychotic patients (1974) (0)
Buspirone-induced prolactin secretion in man is not 5-HT(1A) receptor mediated: Effect of pindolol pretreatment (1992) (0)
Reply to Dr. Verghese and associates (1992) (0)
Summary of discussions (1989) (0)
DST Study Results in Agreement (1985) (0)
The incidence of the serum creatine kinase elevation in schizophrenia and schizoaffective patients during antipsychotic treatment (2003) (0)
S-32-2 Multiple serotonin/dopamine receptor interactions contribute to atypical antipsychotic drug action (1996) (0)
Regular Articles Clozapine for Treatment-Refractory Mania (2019) (0)
SU3. Preliminary Study for Association of Genome-Wide Significant Glutamate Receptor Schizophrenia Risk Variants With Clozapine Response (2017) (0)
Cellular and Pharmacological Studies (1999) (0)
VBR and adolescent onset of schizophrenia (1992) (0)
The critical role of serotonin receptor blockade in the action of clozapine and related atypical antipsychotic drugs (2002) (0)
Reply: H1-histamine Receptor Affinity Predicts Short-term Weight Gain for Typical and Atypical Antipsychotic Drugs (2003) (0)
Effect of (des-Tyr1)-gamma-endorphin on prolactin secretion. (1981) (0)
472. Functional magnetic resonance imaging and schizophrenia (1996) (0)
Chlorpromazine and prolactin studies in schizophrenia (1979) (0)
2013 Daniel H. Efron Research Award (2012) (0)
P.3.e.005 Total blood cholesterol levels and serum creatine kinase activity in violent psychiatric inpatients (2010) (0)
The Biological Basis of Schizophrenia (1980) (0)
Schizophrenia's Multiple Domains (2005) (0)
Cognition, antipsychotic drugs, and treatment response (2000) (0)
Efficacy of Novel Antipsychotic Drugs in Treatment-Refractory Schizophrenia (2010) (0)
Effects of phencyclidine and restraint at 2 degrees C on rat plasma creatine phosphokinase activity. (1973) (0)
Characterization of monoamine oxidase (MAO) in rat skeletal muscle (1975) (0)
A PATH Analytic Approach to Assess the Effects of Antipsychotic Treatment on Depressive Symptoms in Schizoaffective Disorder (2011) (0)

This paper list is powered by the following services:

Other Resources About Herbert Y. Meltzer

en.wikipedia.org

What Schools Are Affiliated With Herbert Y. Meltzer?

Herbert Y. Meltzer is affiliated with the following schools:

Herbert Y. Meltzer's Academic­Influence.com Rankings

Why Is Herbert Y. Meltzer Influential?

Herbert Y. Meltzer's Published Works

Published Works

Other Resources About Herbert Y. Meltzer

What Schools Are Affiliated With Herbert Y. Meltzer?

Herbert Y. Meltzer's AcademicInfluence.com Rankings